| Year |
Citation |
Score |
| 2024 |
Barnes DR, Tyrer JP, Dennis J, Leslie G, Bolla MK, Lush M, Aeilts AM, Aittomäki K, Andrieu N, Andrulis IL, Anton-Culver H, Arason A, Arun BK, Balmaña J, Bandera EV, ... ... Olopade OI, et al. Large-scale genome-wide association study of 398,238 women unveils seven novel loci associated with high-grade serous epithelial ovarian cancer risk. Medrxiv : the Preprint Server For Health Sciences. PMID 38496424 DOI: 10.1101/2024.02.29.24303243 |
0.317 |
|
| 2024 |
Lubinski J, Kotsopoulos J, Moller P, Pal T, Eisen A, Peck L, Karlan BY, Aeilts A, Eng C, Bordeleau L, Foulkes WD, Tung N, Couch FJ, Fruscio R, Ramon Y Cajal T, ... ... Olopade OI, et al. MRI Surveillance and Breast Cancer Mortality in Women With BRCA1 and BRCA2 Sequence Variations. Jama Oncology. PMID 38421676 DOI: 10.1001/jamaoncol.2023.6944 |
0.414 |
|
| 2024 |
Freeman JQ, Sheade JB, Zhao F, Olopade OI, Huo D, Nanda R. Racial differences in familiarity, interest, and use of integrative medicine among patients with breast cancer. Research Square. PMID 38352451 DOI: 10.21203/rs.3.rs-3909360/v1 |
0.311 |
|
| 2024 |
Ochs-Balcom HM, Preus L, Du Z, Elston RC, Teerlink CC, Jia G, Guo X, Cai Q, Long J, Ping J, Li B, Stram DO, Shu XO, Sanderson M, Gao G, ... ... Olopade OI, et al. Novel breast cancer susceptibility loci under linkage peaks identified in African ancestry consortia. Human Molecular Genetics. PMID 38263910 DOI: 10.1093/hmg/ddae002 |
0.429 |
|
| 2024 |
Madorsky Rowdo FP, Xiao G, Khramtsova GF, Nguyen J, Martini R, Stonaker B, Boateng R, Oppong JK, Adjei EK, Awuah B, Kyei I, Aitpillah FS, Adinku MO, Ankomah K, Osei-Bonsu EB, ... ... Olopade OI, et al. Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment. Cancer Letters. 216608. PMID 38199587 DOI: 10.1016/j.canlet.2024.216608 |
0.438 |
|
| 2024 |
Omoleye OJ, Freeman JQ, Oluwasanu M, Adeniji-Sofoluwe A, Woodard AE, Aribisala BS, Adejumo PO, Ntekim A, Makumbi T, Ndom P, Ajayi IO, Olopade OI, Huo D. Benign breast disease and breast cancer risk in African women: a case-control study. Cancer Causes & Control : Ccc. PMID 38177455 DOI: 10.1007/s10552-023-01837-1 |
0.427 |
|
| 2023 |
Kyalwazi B, Yau C, Campbell MJ, Yoshimatsu TF, Chien AJ, Wallace AM, Forero-Torres A, Pusztai L, Ellis ED, Albain KS, Blaes AH, Haley BB, Boughey JC, Elias AD, Clark AS, ... ... Olopade OI, et al. Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer. Jama Network Open. 6: e2349646. PMID 38153734 DOI: 10.1001/jamanetworkopen.2023.49646 |
0.455 |
|
| 2023 |
Vannier AGL, Dhungana A, Zhao F, Chen N, Shubeck S, Hahn OM, Nanda R, Jaskowiak NT, Fleming GF, Olopade OI, Pearson AT, Huo D, Howard FM. Validation of the RSClin risk calculator in the National Cancer Data Base. Cancer. PMID 38146744 DOI: 10.1002/cncr.35163 |
0.363 |
|
| 2023 |
Rowdo FPM, Xiao G, Khramtsova GF, Nguyen J, Olopade OI, Martini R, Stonaker B, Boateng R, Oppong JK, Adjei EK, Awuah B, Kyei I, Aitpillah FS, Adinku MO, Ankomah K, et al. Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment. Biorxiv : the Preprint Server For Biology. PMID 38076873 DOI: 10.1101/2023.06.22.544406 |
0.436 |
|
| 2023 |
Metcalfe K, Huzarski T, Gronwald J, Kotsopoulos J, Kim R, Moller P, Pal T, Aeilts A, Eisen A, Karlan B, Bordeleau L, Tung N, Olopade O, Zakalik D, Singer CF, et al. Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis. British Journal of Cancer. PMID 38030749 DOI: 10.1038/s41416-023-02503-8 |
0.423 |
|
| 2023 |
Adedokun B, Ademola A, Makumbi T, Odedina S, Agwai I, Ndom P, Gakwaya A, Ogundiran T, Ojengbede O, Huo D, Olopade OI. Unawareness of breast cancer family history among African women. The Pan African Medical Journal. 45: 188. PMID 38020349 DOI: 10.11604/pamj.2023.45.188.21616 |
0.352 |
|
| 2023 |
Iwai Y, Toumbou K, Zuze T, Morgan JS, Simwinga L, Wright ST, Fedoriw Y, Oladeru OT, Balogun OD, Roberson ML, Olopade OI, Tomoka T, Elmore SNC. Breast Cancer Germline Genetic Counseling and Testing for Populations of African Heritage Globally: A Scoping Review on Research, Practice, and Bioethical Considerations. Jco Global Oncology. 9: e2300154. PMID 37944088 DOI: 10.1200/GO.23.00154 |
0.426 |
|
| 2023 |
Mapoko BSE, Ndi KC, Tabola L, Mouaye V, Douanla P, Nsangou N, Nkeng G, Vanvolkenburgh C, Dzekem B, Huo D, Ndom P, Olopade O. Feasibility of cancer genetic counselling and screening in Cameroon: perceived benefits and barriers. Ecancermedicalscience. 17: 1588. PMID 37799957 DOI: 10.3332/ecancer.2023.1588 |
0.327 |
|
| 2023 |
Omoleye OJ, Freeman JQ, Oluwasanu M, Adeniji-Sofoluwe A, Woodard AE, Aribisala BS, Adejumo PO, Ntekim A, Makumbi T, Ndom P, Ajayi IO, Olopade OI, Huo D. Benign breast disease and breast cancer risk in African women: A case-control study. Research Square. PMID 37693385 DOI: 10.21203/rs.3.rs-3301977/v1 |
0.398 |
|
| 2023 |
Freeman JQ, Khwaja A, Zhao F, Nanda R, Olopade OI, Huo D. Racial/Ethnic Disparities in Telemedicine Utilization and Satisfaction Among Breast Cancer Patients During the COVID-19 Pandemic: A Mixed-Methods Analysis. Telemedicine Journal and E-Health : the Official Journal of the American Telemedicine Association. PMID 37676974 DOI: 10.1089/tmj.2023.0225 |
0.366 |
|
| 2023 |
Freeman JQ, Sheade J, Zhao F, Olopade OI, Nanda R, Huo D. Demographic and Clinical Characteristics Associated With Familiarity, Interest, and Use of Integrative Therapies Among Patients With Breast Cancer. Integrative Cancer Therapies. 22: 15347354231185122. PMID 37462224 DOI: 10.1177/15347354231185122 |
0.386 |
|
| 2023 |
Kotsopoulos J, Gronwald J, Huzarski T, Aeilts A, Randall Armel S, Karlan B, Singer CF, Eisen A, Tung N, Olopade O, Bordeleau L, Eng C, Foulkes WD, Neuhausen SL, Cullinane CA, et al. Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation. Breast Cancer Research and Treatment. 201: 257-264. PMID 37432545 DOI: 10.1007/s10549-023-06991-3 |
0.419 |
|
| 2023 |
Kaur M, Patterson A, Molina-Vega J, Rothschild H, Clelland E, Ewing CA, Mujir F, Esserman LJ, Olopade OI, Mukhtar RA. Area Deprivation Index in patients with invasive lobular carcinoma of the breast: associations with tumor characteristics and outcomes. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 37257200 DOI: 10.1158/1055-9965.EPI-22-1353 |
0.369 |
|
| 2023 |
Miyashita M, Bell JSK, Wenric S, Karaesmen E, Rhead B, Kase M, Kaneva K, De La Vega FM, Zheng Y, Yoshimatsu TF, Khramtsova G, Liu F, Zhao F, Howard FM, Nanda R, ... ... Olopade OI, et al. Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations. Breast Cancer Research : Bcr. 25: 58. PMID 37231433 DOI: 10.1186/s13058-023-01627-2 |
0.399 |
|
| 2023 |
Gao G, Fiorica PN, McClellan J, Barbeira AN, Li JL, Olopade OI, Im HK, Huo D. A joint transcriptome-wide association study across multiple tissues identifies candidate breast cancer susceptibility genes. American Journal of Human Genetics. PMID 37164006 DOI: 10.1016/j.ajhg.2023.04.005 |
0.425 |
|
| 2023 |
Howard FM, Dolezal J, Kochanny S, Khramtsova G, Vickery J, Srisuwananukorn A, Woodard A, Chen N, Nanda R, Perou CM, Olopade OI, Huo D, Pearson AT. Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrence. Npj Breast Cancer. 9: 25. PMID 37059742 DOI: 10.1038/s41523-023-00530-5 |
0.344 |
|
| 2023 |
Zhao F, Miyashita M, Hattori M, Yoshimatsu T, Howard F, Kaneva K, Jones R, Bell JSK, Fleming GF, Jaskowiak N, Nanda R, Zheng Y, Huo D, Olopade OI. Racial Disparities in Pathological Complete Response Among Patients Receiving Neoadjuvant Chemotherapy for Early-Stage Breast Cancer. Jama Network Open. 6: e233329. PMID 36995716 DOI: 10.1001/jamanetworkopen.2023.3329 |
0.403 |
|
| 2023 |
Shubeck S, Zhao F, Howard FM, Olopade OI, Huo D. Response to Treatment, Racial and Ethnic Disparity, and Survival in Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy in the US. Jama Network Open. 6: e235834. PMID 36995711 DOI: 10.1001/jamanetworkopen.2023.5834 |
0.395 |
|
| 2023 |
McClure MB, Kogure Y, Ansari-Pour N, Saito Y, Chao HH, Shepherd J, Tabata M, Olopade OI, Wedge DC, Hoadley KA, Perou CM, Kataoka K. Landscape of Genetic Alterations Underlying Hallmark Signature Changes in Cancer Reveals Aneuploidy-driven Metabolic Reprogramming. Cancer Research Communications. 3: 281-296. PMID 36860655 DOI: 10.1158/2767-9764.CRC-22-0073 |
0.4 |
|
| 2023 |
Luo J, Kibriya MG, Chen H, Kim K, Ahsan H, Olopade OI, Olopade CS, Aschebrook-Kilfoy B, Huo D. A metabolome-wide case-control study of african american breast cancer patients. Bmc Cancer. 23: 183. PMID 36823587 DOI: 10.1186/s12885-023-10656-1 |
0.427 |
|
| 2023 |
Peiffer DS, Zhao F, Chen N, Hahn OM, Nanda R, Olopade OI, Huo D, Howard FM. Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database. Jama Oncology. PMID 36821125 DOI: 10.1001/jamaoncol.2022.7476 |
0.443 |
|
| 2023 |
Miyashita M, Balogun OB, Olopade OI, Huo D. The optimization of postoperative radiotherapy in de novo stage IV breast cancer: evidence from real-world data to personalize treatment decisions. Scientific Reports. 13: 2880. PMID 36804591 DOI: 10.1038/s41598-023-29888-z |
0.358 |
|
| 2023 |
Mueller SH, Lai AG, Valkovskaya M, Michailidou K, Bolla MK, Wang Q, Dennis J, Lush M, Abu-Ful Z, Ahearn TU, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Aronson KJ, ... ... Olopade OI, et al. Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry. Genome Medicine. 15: 7. PMID 36703164 DOI: 10.1186/s13073-022-01152-5 |
0.372 |
|
| 2022 |
Metcalfe KA, Gronwald J, Tung NM, McCuaig JM, Eisen A, Elser C, Foulkes WD, Neuhausen SL, Senter L, Moller P, Bordeleau L, Fruscio R, Velsher L, Zakalik D, Olopade OI, et al. The risks of cancer in older women with BRCA pathogenic variants: How far have we come? Cancer. PMID 36571512 DOI: 10.1002/cncr.34615 |
0.337 |
|
| 2022 |
Hughes E, Wagner S, Pruss D, Bernhisel R, Probst B, Abkevich V, Simmons T, Hullinger B, Judkins T, Rosenthal E, Roa B, Domchek SM, Eng C, Garber J, Gary M, ... ... Olopade OI, et al. Development and Validation of a Breast Cancer Polygenic Risk Score on the Basis of Genetic Ancestry Composition. Jco Precision Oncology. 6: e2200084. PMID 36331239 DOI: 10.1200/PO.22.00084 |
0.423 |
|
| 2022 |
Gutnik L, Olopade OI, Newman LA, Fayanju OM. Breast cancer among African American and sub-Saharan African women: a tale of global inequities. Cancer Causes & Control : Ccc. 33: 1387-1390. PMID 36239864 DOI: 10.1007/s10552-022-01641-3 |
0.394 |
|
| 2022 |
Ashi K, Ndom P, Gakwaya A, Makumbi T, Olopade OI, Huo D. Validation of the Nigerian Breast Cancer Study Model for Predicting Individual Breast Cancer Risk in Cameroon and Uganda. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 36215182 DOI: 10.1158/1055-9965.EPI-22-0869 |
0.442 |
|
| 2022 |
Hakkaart C, Pearson JF, Marquart L, Dennis J, Wiggins GAR, Barnes DR, Robinson BA, Mace PD, Aittomäki K, Andrulis IL, Arun BK, Azzollini J, Balmaña J, Barkardottir RB, Belhadj S, ... ... Olopade OI, et al. Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers. Communications Biology. 5: 1061. PMID 36203093 DOI: 10.1038/s42003-022-03978-6 |
0.451 |
|
| 2022 |
Mittal A, Deo SVS, Gogia A, Batra A, Kumar A, Bhoriwal S, Deb KS, Dhamija E, Ramprasad VL, Olopade O, Pramanik R. Spectrum and management of breast cancer patients with variant of uncertain significance mutations at a tertiary care centre in North India. Ecancermedicalscience. 16: 1434. PMID 36200007 DOI: 10.3332/ecancer.2022.1434 |
0.447 |
|
| 2022 |
Han YJ, Zhang J, Hardeman A, Liu M, Karginova O, Romero R, Khramtsova GF, Zheng Y, Huo D, Olopade OI. An Enhancer Variant Associated with Breast Cancer Susceptibility in Black Women Regulates TNFSF10 Expression and Antitumor Immunity in Triple-Negative Breast Cancer. Human Molecular Genetics. PMID 35930348 DOI: 10.1093/hmg/ddac168 |
0.425 |
|
| 2022 |
Hardeman AA, Han YJ, Grushko TA, Mueller J, Gomez MJ, Zheng Y, Olopade OI. Subtype-specific expression of MELK is partly due to copy number alterations in breast cancer. Plos One. 17: e0268693. PMID 35749404 DOI: 10.1371/journal.pone.0268693 |
0.443 |
|
| 2022 |
Ntekim A, Olopade OI. Innovative Strategies for Developing Biomarker-Informed Cancer Clinical Trials to Accelerate Progress in Precision Oncology in Sub-Saharan Africa. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 42: 1-9. PMID 35687824 DOI: 10.1200/EDBK_349955 |
0.309 |
|
| 2022 |
Gao G, Zhao F, Ahearn TU, Lunetta KL, Troester MA, Du Z, Ogundiran TO, Ojengbede O, Blot W, Nathanson KL, Domchek SM, Nemesure B, Hennis A, Ambs S, McClellan J, ... ... Olopade OI, et al. Polygenic Risk Scores for Prediction of Breast Cancer Risk in Women of African Ancestry: a Cross-Ancestry Approach. Human Molecular Genetics. PMID 35554533 DOI: 10.1093/hmg/ddac102 |
0.401 |
|
| 2022 |
Kotsopoulos J, Lubiński J, Gronwald J, Menkiszak J, McCuaig J, Metcalfe K, Foulkes WD, Neuhausen SL, Sun S, Karlan BY, Eisen A, Tung N, Olopade OI, Couch FJ, Huzarski T, et al. Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: a Reappraisal. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 35477169 DOI: 10.1158/1055-9965.EPI-21-1196 |
0.485 |
|
| 2022 |
Felix GES, Guindalini RSC, Zheng Y, Walsh T, Sveen E, Lopes TMM, Côrtes J, Zhang J, Carôzo P, Santos I, Bonfim TF, Garicochea B, Toralles MBP, Meyer R, Netto EM, ... ... Olopade OI, et al. Mutational spectrum of breast cancer susceptibility genes among women ascertained in a cancer risk clinic in Northeast Brazil. Breast Cancer Research and Treatment. PMID 35353237 DOI: 10.1007/s10549-022-06560-0 |
0.421 |
|
| 2022 |
Pollock NC, Ramroop JR, Hampel H, Troester MA, Conway K, Hu JJ, Freudenheim JL, Olopade OI, Huo D, Ziv E, Neuhausen SL, Stevens P, McElroy JP, Toland AE. Differences in somatic TP53 mutation type in breast tumors by race and receptor status. Breast Cancer Research and Treatment. PMID 35286522 DOI: 10.1007/s10549-022-06509-3 |
0.418 |
|
| 2022 |
Guindalini RSC, Viana DV, Kitajima JPFW, Rocha VM, López RVM, Zheng Y, Freitas É, Monteiro FPM, Valim A, Schlesinger D, Kok F, Olopade OI, Folgueira MAAK. Detection of germline variants in Brazilian breast cancer patients using multigene panel testing. Scientific Reports. 12: 4190. PMID 35264596 DOI: 10.1038/s41598-022-07383-1 |
0.326 |
|
| 2022 |
Dareng EO, Tyrer JP, Barnes DR, Jones MR, Yang X, Aben KKH, Adank MA, Agata S, Andrulis IL, Anton-Culver H, Antonenkova NN, Aravantinos G, Arun BK, Augustinsson A, Balmaña J, ... ... Olopade OI, et al. Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics : Ejhg. PMID 35027648 DOI: 10.1038/s41431-021-00987-7 |
0.308 |
|
| 2021 |
Ansari-Pour N, Zheng Y, Yoshimatsu TF, Sanni A, Ajani M, Reynier JB, Tapinos A, Pitt JJ, Dentro S, Woodard A, Rajagopal PS, Fitzgerald D, Gruber AJ, Odetunde A, Popoola A, ... ... Olopade OI, et al. Whole-genome analysis of Nigerian patients with breast cancer reveals ethnic-driven somatic evolution and distinct genomic subtypes. Nature Communications. 12: 6946. PMID 34836952 DOI: 10.1038/s41467-021-27079-w |
0.401 |
|
| 2021 |
Mittal A, Deo S, Gogia A, Batra A, Kumar A, Bhoriwal S, Deb KS, Dhamija E, Thulkar S, Ramprasad VL, Olopade O, Pramanik R. ASO Visual Abstract: Profile of Pathogenic Mutations and Evaluation of Germline Genetic Testing Criteria in Consecutive Breast Cancer Patients Treated at a North Indian Tertiary Care Center. Annals of Surgical Oncology. PMID 34825284 DOI: 10.1245/s10434-021-10967-2 |
0.369 |
|
| 2021 |
Adejumo PO, Aniagwu TIG, Awolude OA, Oni AO, Ajayi OO, Fagbenle O, Ogungbade D, Kochheiser M, Ogundiran T, Olopade OI. Feasibility of genetic testing for cancer risk assessment programme in Nigeria. Ecancermedicalscience. 15: 1283. PMID 34824606 DOI: 10.3332/ecancer.2021.1283 |
0.445 |
|
| 2021 |
Mittal A, Deo SVS, Gogia A, Batra A, Kumar A, Bhoriwal S, Deb KS, Dhamija E, Thulkar S, Ramprasad VL, Olopade O, Pramanik R. Profile of Pathogenic Mutations and Evaluation of Germline Genetic Testing Criteria in Consecutive Breast Cancer Patients Treated at a North Indian Tertiary Care Center. Annals of Surgical Oncology. PMID 34601666 DOI: 10.1245/s10434-021-10870-w |
0.44 |
|
| 2021 |
Olopade OI. Doing better and being better in breast cancer care: an interview with Funmi Olopade. Disease Models & Mechanisms. 14. PMID 34549779 DOI: 10.1242/dmm.049198 |
0.393 |
|
| 2021 |
Kim SJ, Lubiński J, Huzarski T, Møller P, Armel S, Karlan BY, Senter L, Eisen A, Foulkes WD, Singer CF, Tung N, Bordeleau L, Neuhausen SL, Olopade OI, Eng C, et al. Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 34426412 DOI: 10.1158/1055-9965.EPI-21-0296 |
0.32 |
|
| 2021 |
Barnes DR, Silvestri V, Leslie G, McGuffog L, Dennis J, Yang X, Adlard J, Agnarsson BA, Ahmed M, Aittomäki K, Andrulis IL, Arason A, Arnold N, Auber B, Azzollini J, ... ... Olopade OI, et al. Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. Journal of the National Cancer Institute. PMID 34320204 DOI: 10.1093/jnci/djab147 |
0.385 |
|
| 2021 |
Zhao F, Henderson TO, Cipriano TM, Copley BL, Liu M, Burra R, Birch SH, Olopade OI, Huo D. The impact of coronavirus disease 2019 on the quality of life and treatment disruption of patients with breast cancer in a multiethnic cohort. Cancer. PMID 34292583 DOI: 10.1002/cncr.33798 |
0.348 |
|
| 2021 |
Adedokun B, Du Z, Gao G, Ahearn TU, Lunetta KL, Zirpoli G, Figueroa J, John EM, Bernstein L, Zheng W, Hu JJ, Ziegler RG, Nyante S, Bandera EV, Ingles SA, ... ... Olopade OI, et al. Cross-ancestry GWAS meta-analysis identifies six breast cancer loci in African and European ancestry women. Nature Communications. 12: 4198. PMID 34234117 DOI: 10.1038/s41467-021-24327-x |
0.443 |
|
| 2021 |
Lakeman IMM, van den Broek AJ, Vos JAM, Barnes DR, Adlard J, Andrulis IL, Arason A, Arnold N, Arun BK, Balmaña J, Barrowdale D, Benitez J, Borg A, Caldés T, Caligo MA, ... ... Olopade OI, et al. The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 34113011 DOI: 10.1038/s41436-021-01198-7 |
0.44 |
|
| 2021 |
Coignard J, Lush M, Beesley J, O'Mara TA, Dennis J, Tyrer JP, Barnes DR, McGuffog L, Leslie G, Bolla MK, Adank MA, Agata S, Ahearn T, Aittomäki K, Andrulis IL, ... ... Olopade OI, et al. Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nature Communications. 12: 2986. PMID 33990587 DOI: 10.1038/s41467-021-23162-4 |
0.413 |
|
| 2021 |
Hand T, Rosseau NA, Stiles CE, Sheih T, Ghandakly E, Oluwasanu M, Olopade OI. The global role, impact, and limitations of Community Health Workers (CHWs) in breast cancer screening: a scoping review and recommendations to promote health equity for all. Global Health Action. 14: 1883336. PMID 33899695 DOI: 10.1080/16549716.2021.1883336 |
0.324 |
|
| 2021 |
Du Z, Gao G, Adedokun B, Ahearn T, Lunetta KL, Zirpoli G, Troester MA, Ruiz-Narváez EA, Haddad SA, Pal Choudhury P, Figueroa J, John EM, Bernstein L, Zheng W, Hu JJ, ... ... Olopade OI, et al. Evaluating Polygenic Risk Scores for Breast Cancer in Women of African Ancestry. Journal of the National Cancer Institute. PMID 33769540 DOI: 10.1093/jnci/djab050 |
0.38 |
|
| 2021 |
Fatiregun OA, Oluokun T, Lasebikan NN, Nwachukwu E, Ibraheem AA, Olopade O. Breast Cancer Research to Support Evidence-Based Medicine in Nigeria: A Review of the Literature. Jco Global Oncology. 7: 384-390. PMID 33720754 DOI: 10.1200/GO.20.00541 |
0.381 |
|
| 2021 |
Coignard J, Lush M, Beesley J, O'Mara TA, Dennis J, Tyrer JP, Barnes DR, McGuffog L, Leslie G, Bolla MK, Adank MA, Agata S, Ahearn T, Aittomäki K, Andrulis IL, ... ... Olopade OI, et al. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nature Communications. 12: 1078. PMID 33597508 DOI: 10.1038/s41467-020-20496-3 |
0.364 |
|
| 2021 |
Shang L, Hattori M, Fleming G, Jaskowiak N, Hedeker D, Olopade OI, Huo D. Impact of post-diagnosis weight change on survival outcomes in Black and White breast cancer patients. Breast Cancer Research : Bcr. 23: 18. PMID 33541403 DOI: 10.1186/s13058-021-01397-9 |
0.312 |
|
| 2021 |
Howard FM, Olopade OI. Epidemiology of Triple-Negative Breast Cancer: A Review. Cancer Journal (Sudbury, Mass.). 27: 8-16. PMID 33475288 DOI: 10.1097/PPO.0000000000000500 |
0.486 |
|
| 2021 |
Han YJ, Zhang J, Lee JH, Mason JM, Karginova O, Yoshimatsu TF, Hao Q, Hurley I, Paré Brunet L, Prat A, Prasanth KV, Gack MU, Olopade OI. The BRCA1 Pseudogene Negatively Regulates Anti-Tumor Responses through Inhibition of Innate Immune Defense Mechanisms. Cancer Research. PMID 33472891 DOI: 10.1158/0008-5472.CAN-20-1959 |
0.32 |
|
| 2021 |
Hughes E, Tiemeny P, Gallagher S, Meek S, Eng C, Gary M, Gordon O, Klemp JR, Olopade OI, Pederson HJ, Weitzel JN, Whitworth PW, Yehia L, Wagner S, Slavin TP, et al. Ancestrally unbiased polygenic breast cancer (BC) risk assessment. Journal of Clinical Oncology. 39: 10502-10502. DOI: 10.1200/JCO.2021.39.15_SUPPL.10502 |
0.365 |
|
| 2021 |
Kim S, Lubinski J, Huzarski T, Moller P, Armel S, Karlan B, Senter L, Eisen A, Foulkes W, Singer C, Tung N, Bordeleau L, Neuhausen S, Olopade O, Eng C, et al. Weight gain and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers Molecular Genetics and Metabolism. 132: S357-S358. DOI: 10.1016/S1096-7192(21)00626-0 |
0.335 |
|
| 2020 |
Zhao F, Copley B, Niu Q, Liu F, Johnson JA, Sutton T, Khramtsova G, Sveen E, Yoshimatsu TF, Zheng Y, Ibraheem A, Jaskowiak N, Nanda R, Fleming GF, Olopade OI, et al. Racial disparities in survival outcomes among breast cancer patients by molecular subtypes. Breast Cancer Research and Treatment. PMID 33111220 DOI: 10.1007/s10549-020-05984-w |
0.418 |
|
| 2020 |
Kotsopoulos J, Gronwald J, McCuaig JM, Karlan BY, Eisen A, Tung N, Bordeleau L, Senter L, Eng C, Couch F, Fruscio R, Weitzel JN, Olopade O, Singer CF, Pal T, et al. Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecologic Oncology. PMID 33010967 DOI: 10.1016/j.ygyno.2020.09.037 |
0.372 |
|
| 2020 |
Mustafi D, Valek R, Fitch M, Werner V, Fan X, Markiewicz E, Fernandez S, Zamora M, Mueller J, Olopade OI, Conzen SD, Brady MJ, Karczmar GS. Magnetic resonance angiography reveals increased arterial blood supply and tumorigenesis following high fat feeding in a mouse model of triple-negative breast cancer. Nmr in Biomedicine. 33: e4363. PMID 32881124 DOI: 10.1002/Nbm.4363 |
0.375 |
|
| 2020 |
Powers-James C, Alvarez A, Milbury K, Barbo A, Daunov K, Lopez G, Cohen L, Delgado-Guay MO, Olopade OI, Lee RT. The Influence of Spirituality and Religiosity on US Oncologists' Personal Use of and Clinical Practices Regarding Complementary and Alternative Medicine. Integrative Cancer Therapies. 19: 1534735420945769. PMID 32830556 DOI: 10.1177/1534735420945769 |
0.31 |
|
| 2020 |
Ntekim A, Ibraheem A, Adeniyi-Sofoluwe A, Adepoju T, Oluwasanu M, Aniagwu T, Awolude O, Balogun W, Kotila O, Adejumo P, Babalola CP, Arinola G, Ojengbede O, Olopade CO, Olopade OI. Implementing oncology clinical trials in Nigeria: a model for capacity building. Bmc Health Services Research. 20: 713. PMID 32746811 DOI: 10.1186/S12913-020-05561-3 |
0.331 |
|
| 2020 |
Oluwasanu M, Olopade OI. Global disparities in breast cancer outcomes: new perspectives, widening inequities, unanswered questions. The Lancet. Global Health. 8: e978-e979. PMID 32710868 DOI: 10.1016/S2214-109X(20)30307-7 |
0.483 |
|
| 2020 |
Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, Chen YY, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, ... ... Olopade O, et al. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. Jama Oncology. PMID 32701140 DOI: 10.1001/Jamaoncol.2020.2535 |
0.355 |
|
| 2020 |
Barnes DR, Rookus MA, McGuffog L, Leslie G, Mooij TM, Dennis J, Mavaddat N, Adlard J, Ahmed M, Aittomäki K, Andrieu N, Andrulis IL, Arnold N, Arun BK, Azzollini J, ... ... Olopade OI, et al. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 32665703 DOI: 10.1038/S41436-020-0862-X |
0.527 |
|
| 2020 |
Whitaker KD, Sheth D, Olopade OI. Dynamic contrast-enhanced magnetic resonance imaging for risk-stratified screening in women with BRCA mutations or high familial risk for breast cancer: are we there yet? Breast Cancer Research and Treatment. 183: 243-250. PMID 32621252 DOI: 10.1007/S10549-020-05759-3 |
0.486 |
|
| 2020 |
Silvestri V, Leslie G, Barnes DR, Agnarsson BA, Aittomäki K, Alducci E, Andrulis IL, Barkardottir RB, Barroso A, Barrowdale D, Benitez J, Bonanni B, Borg A, Buys SS, ... ... Olopade OI, et al. Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Jama Oncology. PMID 32614418 DOI: 10.1001/Jamaoncol.2020.2134 |
0.51 |
|
| 2020 |
Liu J, Prager-van der Smissen WJC, Collée JM, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Arnold N, ... ... Olopade OI, et al. Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. Scientific Reports. 10: 9688. PMID 32546843 DOI: 10.1038/S41598-020-65665-Y |
0.578 |
|
| 2020 |
Ibraheem A, Olopade OI, Huo D. Propensity score analysis of the prognostic value of genomic assays for breast cancer in diverse populations using the National Cancer Data Base. Cancer. PMID 32521056 DOI: 10.1002/Cncr.32956 |
0.489 |
|
| 2020 |
Lee RT, Amico A, Malaka D, Lewin R, Cummings SA, Verp M, Patrick-Miller L, Bradbury AR, Olopade OI. Utilization of Complementary Alternative Medicine, Diet, and Exercise Among Women at High Risk for Developing Breast Cancer. Integrative Cancer Therapies. 19: 1534735420922610. PMID 32448019 DOI: 10.1177/1534735420922610 |
0.469 |
|
| 2020 |
Zhang H, Ahearn TU, Lecarpentier J, Barnes D, Beesley J, Qi G, Jiang X, O'Mara TA, Zhao N, Bolla MK, Dunning AM, Dennis J, Wang Q, Ful ZA, Aittomäki K, ... ... Olopade OI, et al. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics. PMID 32424353 DOI: 10.1038/s41588-020-0609-2 |
0.447 |
|
| 2020 |
O'Donnell PH, Trubetskoy V, Nurhussein-Patterson A, Hall JP, Nath A, Huo D, Fleming GF, Ingle JN, Abramson VG, Morrow PK, Storniolo AM, Forero A, Van Poznak C, Liu MC, Chang JC, ... ... Olopade OI, et al. Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. Breast Cancer Research and Treatment. PMID 32378051 DOI: 10.1007/S10549-020-05603-8 |
0.506 |
|
| 2020 |
Pruitt LCC, Odedina S, Anetor I, Mumuni T, Oduntan H, Ademola A, Morhason-Bello IO, Ogundiran TO, Obajimi M, Ojengbede OA, Olopade OI. Breast Cancer Knowledge Assessment of Health Workers in Ibadan, Southwest Nigeria. Jco Global Oncology. 6: 387-394. PMID 32125900 DOI: 10.1200/JGO.19.00260 |
0.382 |
|
| 2020 |
Feng H, Gusev A, Pasaniuc B, Wu L, Long J, Abu-Full Z, Aittomäki K, Andrulis IL, Anton-Culver H, Antoniou AC, Arason A, Arndt V, Aronson KJ, Arun BK, Asseryanis E, ... ... Olopade OI, et al. Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. Genetic Epidemiology. PMID 32115800 DOI: 10.1002/gepi.22288 |
0.451 |
|
| 2020 |
Hamlish T, Liu L, Zhang Z, Sohmer D, Moton Z, Johnson D, Frolova A, Olopade O, Hong S. Care Coordination for Breast Cancer Survivors in Urban Underserved Communities: Will Treatment Summaries and Survivorship Care Plans Be Enough? Journal of Racial and Ethnic Health Disparities. PMID 31900747 DOI: 10.1007/S40615-019-00687-5 |
0.39 |
|
| 2020 |
Swisher EM, Rayes N, Bowen D, Peterson CB, Coffin T, Norquist B, Gavin K, Polinsky D, Crase J, Bakkum-Gamez JN, Blank SV, Munsell MF, Nebgen DR, Pradeep H, Law S, ... Olopade OI, et al. Results from MAGENTA: A national randomized four-arm noninferiority trial evaluating pre- and post-test genetic counseling during online testing for breast and ovarian cancer genetic risk. Journal of Clinical Oncology. 38: 1506-1506. DOI: 10.1200/Jco.2020.38.15_Suppl.1506 |
0.4 |
|
| 2020 |
Huo D, Beaubier N, Jaskowiak N, Nanda R, Fleming G, Hattori M, Rajagopal PS, Ibraheem A, Copley B, Niu Q, Liu F, Sveen E, Yoshimatsu T, Khramtsova G, Zheng Y, ... ... Olopade O, et al. Abstract B123: Using eHealth and data science to dissect breast cancer heterogeneity in the Chicago Multi-Ethnic (ChiMEC) Breast Cancer Cohort Cancer Epidemiology, Biomarkers & Prevention. DOI: 10.1158/1538-7755.Disp19-B123 |
0.529 |
|
| 2020 |
Semprini JT, Olopade O. Abstract B059: Can health system engagement facilitate greater utilization of genetic tests to predict cancer risk? A health disparities exploration of national survey data Cancer Epidemiology, Biomarkers & Prevention. DOI: 10.1158/1538-7755.Disp19-B059 |
0.337 |
|
| 2020 |
Hattori M, Huo D, Beaubier N, Rajagopal PS, Yoshimatsu T, Zheng Y, Sveen E, Khramtsova G, Liu F, Abboushi T, White K, Olopade O. Abstract P4-05-10: Comparative analysis of genomic landscape reveals heterogeneity in HER2-positive primary breast cancers and residual disease following neoadjuvant therapy Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P4-05-10 |
0.527 |
|
| 2020 |
Theiner S, Hu D, Huntsman S, Shieh Y, Fejerman L, Acerbi I, Sawyer SD, Kendall P, Zheng W, Huo D, Olopade OI, Haiman C, Kerlikowske K, Cummings S, John E, et al. Abstract P2-10-05: A breast cancer multi-racial/ethnic polygenic risk score for improved personalized breast cancer screening Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P2-10-05 |
0.497 |
|
| 2020 |
Che M, Fiscallini AS, Acerbi I, Shieh Y, Madlensky L, Tice J, Ziv E, Eklund M, Blanco A, Tong B, Goodman D, Nassereddine L, Anderson N, Harvey H, Fors S, ... ... Olopade OI, et al. Abstract OT3-03-02: Personalized breast cancer screening in a population-based study: Women informed to screen depending on measures of risk (WISDOM) Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Ot3-03-02 |
0.504 |
|
| 2020 |
Adedokun B, Du Z, Gao G, Ahearn T, Lunetta KL, Zirpoli G, Figueroa J, John EM, Bernstein L, Zheng W, Hu JJ, Ziegler RG, Nyante S, Bandera EV, Ingles SA, ... ... Olopade OI, et al. Abstract 4613: Cross-ancestry genome-wide association study identifies six new loci for breast cancer in women of African and european ancestry Epidemiology. DOI: 10.1158/1538-7445.Am2020-4613 |
0.479 |
|
| 2020 |
Jia G, Ping J, Yang Y, Sanderson M, Cai Q, Guo X, Blot WJ, Li B, Bandera EV, Bolla MK, García-Closas M, Easton DF, Fadden MK, Gu J, Huo D, ... ... Olopade OI, et al. Abstract 28: Integrating genomic and transcriptomic data to identify genetic loci associated with breast cancer risk in women of African ancestry Epidemiology. DOI: 10.1158/1538-7445.Am2020-28 |
0.493 |
|
| 2020 |
Du Z, Gao G, Adedokun B, Ahearn T, Lunetta KL, Zirpoli G, Troester M, Ruiz-Narváez EA, Haddad S, Figueroa J, John EM, Bernstein L, Zheng W, Hu JJ, Ziegler RG, ... ... Olopade OI, et al. Abstract 2320: Evaluating a polygenic risk score for breast cancer in women of African ancestry Epidemiology. 80: 2320-2320. DOI: 10.1158/1538-7445.Am2020-2320 |
0.535 |
|
| 2019 |
Adedokun B, Zheng Y, Ndom P, Gakwaya A, Makumbi T, Zhou AY, Yoshimatsu TF, Rodriguez A, Madduri RK, Foster IT, Sallam A, Olopade OI, Huo D. Prevalence of Inherited Mutations in Breast Cancer Predisposition Genes among Uganda and Cameroon Women. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 31871109 DOI: 10.1158/1055-9965.Epi-19-0506 |
0.553 |
|
| 2019 |
Yang X, Leslie G, Doroszuk A, Schneider S, Allen J, Decker B, Dunning AM, Redman J, Scarth J, Plaskocinska I, Luccarini C, Shah M, Pooley K, Dorling L, Lee A, ... ... Olopade OI, et al. Cancer Risks Associated With Germline Pathogenic Variants: An International Study of 524 Families. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1901907. PMID 31841383 DOI: 10.1200/Jco.19.01907 |
0.507 |
|
| 2019 |
Xiao G, Lundine D, Annor GK, Canar J, Ellison V, Polotskaia A, Donabedian PL, Reiner T, Khramtsova GF, Olopade OI, Mazo A, Bargonetti J. Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer. Cancer Research. PMID 31776133 DOI: 10.1158/0008-5472.Can-19-1036 |
0.497 |
|
| 2019 |
Patel VL, Busch EL, Friebel TM, Cronin A, Leslie G, McGuffog L, Adlard J, Agata S, Agnarsson BA, Ahmed M, Aittomäki K, Alducci E, Andrulis IL, Arason A, Arnold N, ... ... Olopade OI, et al. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Research. PMID 31723001 DOI: 10.1158/0008-5472.Can-19-1840 |
0.382 |
|
| 2019 |
Figlioli G, Bogliolo M, Catucci I, Caleca L, Lasheras SV, Pujol R, Kiiski JI, Muranen TA, Barnes DR, Dennis J, Michailidou K, Bolla MK, Leslie G, Aalfs CM, ... ... Olopade OI, et al. The :p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. Npj Breast Cancer. 5: 38. PMID 31700994 DOI: 10.1038/s41523-019-0127-5 |
0.453 |
|
| 2019 |
Royston KJ, Adedokun B, Olopade OI. Race, the microbiome and colorectal cancer. World Journal of Gastrointestinal Oncology. 11: 773-787. PMID 31662819 DOI: 10.4251/Wjgo.V11.I10.773 |
0.429 |
|
| 2019 |
Jiang X, Finucane HK, Schumacher FR, Schmit SL, Tyrer JP, Han Y, Michailidou K, Lesseur C, Kuchenbaecker KB, Dennis J, Conti DV, Casey G, Gaudet MM, Huyghe JR, Albanes D, ... ... Olopade OI, et al. Publisher Correction: Shared heritability and functional enrichment across six solid cancers. Nature Communications. 10: 4386. PMID 31548585 DOI: 10.1038/S41467-019-12095-8 |
0.358 |
|
| 2019 |
Lin S, Yu L, Song X, Bi J, Jiang L, Wang Y, He M, Xiao Q, Sun M, Olopade OI, Zhao L, Wei M. Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response. Cell Death & Disease. 10: 666. PMID 31511498 DOI: 10.1038/S41419-019-1871-Z |
0.402 |
|
| 2019 |
Dörk T, Peterlongo P, Mannermaa A, Bolla MK, Wang Q, Dennis J, Ahearn T, Andrulis IL, Anton-Culver H, Arndt V, Aronson KJ, Augustinsson A, Freeman LEB, Beckmann MW, Beeghly-Fadiel A, ... ... Olopade OI, et al. Two truncating variants in FANCC and breast cancer risk. Scientific Reports. 9: 12524. PMID 31467304 DOI: 10.1038/s41598-019-48804-y |
0.469 |
|
| 2019 |
Chen Q, Deng X, Hu X, Guan S, He M, Wang Y, Wei B, Zhang J, Zhao H, Yao W, Jin F, Liu Y, Chen J, Olopade OI, Wu H, et al. Breast cancer risk-associated SNPs in the mTOR promoter form de novo KLF5 and ZEB1 binding sites that influence the cellular response to paclitaxel. Molecular Cancer Research : McR. PMID 31467112 DOI: 10.1158/1541-7786.MCR-18-1072 |
0.312 |
|
| 2019 |
West AH, Knollman H, Dugan J, Hedeker D, Handorf EA, Nielsen SM, Bealin LC, Goldblatt LG, Willems H, Daly MB, Afghahi A, Olopade OI, Hulick PJ, Shagisultanova E, Huo D, et al. Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: A retrospective matched cohort study. Cancer Medicine. PMID 31407530 DOI: 10.1002/Cam4.2471 |
0.47 |
|
| 2019 |
Yeh AC, Li H, Zhu Y, Zhang J, Khramtsova G, Drukker K, Edwards A, McGregor S, Yoshimatsu T, Zheng Y, Niu Q, Abe H, Mueller J, Conzen S, Ji Y, ... ... Olopade OI, et al. Radiogenomics of breast cancer using dynamic contrast enhanced MRI and gene expression profiling. Cancer Imaging : the Official Publication of the International Cancer Imaging Society. 19: 48. PMID 31307537 DOI: 10.1186/S40644-019-0233-5 |
0.439 |
|
| 2019 |
Rajagopal PS, Catenacci DVT, Olopade OI. The Time for Mainstreaming Germline Testing for Patients With Breast Cancer Is Now. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1900160. PMID 31246531 DOI: 10.1200/Jco.19.00160 |
0.514 |
|
| 2019 |
Qian F, Rookus MA, Leslie G, Risch HA, Greene MH, Aalfs CM, Adank MA, Adlard J, Agnarsson BA, Ahmed M, Aittomäki K, Andrulis IL, Arnold N, Arun BK, Ausems MGEM, ... ... Olopade OI, et al. Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. British Journal of Cancer. PMID 31213659 DOI: 10.1038/S41416-019-0492-8 |
0.417 |
|
| 2019 |
Wang S, Pitt JJ, Zheng Y, Yoshimatsu TF, Gao G, Sanni A, Oluwasola O, Ajani M, Fitzgerald D, Odetunde A, Khramtsova G, Hurley I, Popoola A, Falusi A, Ogundiran T, ... ... Olopade OI, et al. Germline variants and somatic mutation signatures of breast cancer across populations of African and European ancestry in the US and Nigeria. International Journal of Cancer. PMID 31173346 DOI: 10.1002/Ijc.32498 |
0.491 |
|
| 2019 |
Friebel TM, Andrulis IL, Balmaña J, Blanco AM, Couch FJ, Daly MB, Domchek SM, Easton DF, Foulkes WD, Ganz PA, Garber J, Glendon G, Greene MH, Hulick PJ, Isaacs C, ... ... Olopade OI, et al. BRCA1 and BRCA2 Pathogenic Sequence Variants in Women of African Origin or Ancestry. Human Mutation. PMID 31112363 DOI: 10.1002/Humu.23804 |
0.419 |
|
| 2019 |
Ferreira MA, Gamazon ER, Al-Ejeh F, Aittomäki K, Andrulis IL, Anton-Culver H, Arason A, Arndt V, Aronson KJ, Arun BK, Asseryanis E, Azzollini J, Balmaña J, Barnes DR, Barrowdale D, ... ... Olopade OI, et al. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications. 10: 1741. PMID 30988301 DOI: 10.1038/s41467-018-08053-5 |
0.441 |
|
| 2019 |
Karginova O, Weekley CM, Raoul A, Alsayed A, Wu T, Lee SS, He C, Olopade OI. Inhibition of Copper Transport Induces Apoptosis in Triple Negative Breast Cancer Cells and Suppresses Tumor Angiogenesis. Molecular Cancer Therapeutics. PMID 30824611 DOI: 10.1158/1535-7163.Mct-18-0667 |
0.415 |
|
| 2019 |
Antoniou A, Anton-Culver H, Borowsky A, Broeders M, Brooks J, Chiarelli A, Chiquette J, Cuzick J, Delaloge S, Devilee P, Dorval M, Easton D, Eisen A, Eklund M, Eloy L, ... ... Olopade O, et al. A response to "Personalised medicine and population health: breast and ovarian cancer". Human Genetics. PMID 30810870 DOI: 10.1007/S00439-019-01984-Z |
0.442 |
|
| 2019 |
Kotsopoulos J, Lubinski J, Lynch HT, Tung N, Armel S, Senter L, Singer CF, Fruscio R, Couch F, Weitzel JN, Karlan B, Foulkes WD, Moller P, Eisen A, Ainsworth P, ... ... Olopade O, et al. Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment. PMID 30756284 DOI: 10.1007/S10549-019-05162-7 |
0.567 |
|
| 2019 |
Metcalfe K, Lynch HT, Foulkes WD, Tung N, Olopade OI, Eisen A, Lerner-Ellis J, Snyder C, Kim SJ, Sun P, Narod SA. Oestrogen receptor status and survival in women with BRCA2-associated breast cancer. British Journal of Cancer. PMID 30723304 DOI: 10.1038/S41416-019-0376-Y |
0.527 |
|
| 2019 |
Jiang X, Finucane HK, Schumacher FR, Schmit SL, Tyrer JP, Han Y, Michailidou K, Lesseur C, Kuchenbaecker KB, Dennis J, Conti DV, Casey G, Gaudet MM, Huyghe JR, Albanes D, ... ... Olopade OI, et al. Shared heritability and functional enrichment across six solid cancers. Nature Communications. 10: 431. PMID 30683880 DOI: 10.1038/S41467-018-08054-4 |
0.506 |
|
| 2019 |
Pitt JJ, Riester M, Zheng Y, Yoshimatsu TF, Sanni A, Oluwasola O, Veloso A, Labrot E, Wang S, Odetunde A, Ademola A, Okedere B, Mahan S, Leary R, Macomber M, ... ... Olopade OI, et al. Author Correction: Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features. Nature Communications. 10: 288. PMID 30643118 DOI: 10.1038/S41467-018-07886-4 |
0.384 |
|
| 2019 |
Hoffman J, Fejerman L, Hu D, Huntsman S, Li M, John EM, Torres-Mejia G, Kushi L, Ding YC, Weitzel J, Neuhausen SL, Lott P, Echeverry M, Carvajal-Carmona L, ... ... Olopade O, et al. Identification of novel common breast cancer risk variants at the 6q25 locus among Latinas. Breast Cancer Research : Bcr. 21: 3. PMID 30642363 DOI: 10.1186/S13058-018-1085-9 |
0.526 |
|
| 2019 |
Semprini J, Olopade OI. Evaluating the Effect of Medicaid Expansion on Black/White Breast Cancer Mortality Disparities: A Difference-in-Difference Analysis Journal of Global Oncology. 5: 10-10. DOI: 10.1200/Jgo.19.19000 |
0.478 |
|
| 2019 |
Odedina SO, Ajayi IO, Morhason-Bello IO, Babatundetuk A, Huo D, Olopade OI, Ojengbede OA. Influence of a Teaching Session on Breast Self-Examination and Adherence Among Pregnant and Lactating Women in Ibadan, Nigeria Journal of Global Oncology. 5: 9-9. DOI: 10.1200/Jgo.19.18000 |
0.469 |
|
| 2019 |
Li S, Huo D, Ojengbede O, Olopade O. Breast Cancer and the Environment: A Pilot Study of Nigerian Women Journal of Global Oncology. 5: 5-5. DOI: 10.1200/Jgo.19.14000 |
0.502 |
|
| 2019 |
Kochheiser ML, Aniagwu TIG, Adejumo PO, Olopade OI. Genetic Testing for Cancer Risk Assessment in Patients With Breast and Ovarian Cancer in Ibadan, Nigeria Journal of Global Oncology. 5: 4-4. DOI: 10.1200/Jgo.19.13000 |
0.516 |
|
| 2019 |
Leng J, Ibraheem AF, Ntekim AI, Popoola A, Agaga L, Ukoh E, Golden DW, Olopade OI. Survey of medical student knowledge in oncology and survivorship care in Nigeria: A pilot study. Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.E18106 |
0.309 |
|
| 2019 |
Abdulkareem FB, Khramtsova G, Adedokun B, Rotimi O, Abudu K, Badmos K, Ibraheem AF, Khramtsov A, Sveen L, Hurley I, Masaya H, Huo D, Olopade OI. Colorectal cancer molecular subtypes by immunohistochemistry in a patient cohort from Nigeria. Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.E15145 |
0.397 |
|
| 2019 |
Swoboda AT, Sharma A, Olopade OI, Nanda R, Gilbert J. Characterizing the gut microbiome of patients with triple-negative breast cancer. Journal of Clinical Oncology. 37: e14186-e14186. DOI: 10.1200/Jco.2019.37.15_Suppl.E14186 |
0.359 |
|
| 2019 |
Hattori M, Rajagopal PS, Sveen L, Khramtsova G, Yoshimatsu T, Beaubier N, Barber M, Abboushi T, Fang L, Zheng Y, White K, Huo D, Olopade OI. Genomic profiling of residual tumor after neoadjuvant chemotherapy for breast cancer. Journal of Clinical Oncology. 37: e12106-e12106. DOI: 10.1200/Jco.2019.37.15_Suppl.E12106 |
0.513 |
|
| 2019 |
Rajagopal PS, Beaubier N, Hattori M, Sveen L, Khramtsova G, Abboushi T, Barber M, Liu F, Yoshimatsu T, Zheng Y, White K, Huo D, Olopade OI. Determining clinical relevance of genomic heterogeneity in an ethnically diverse cohort of newly diagnosed patients with breast cancer. Journal of Clinical Oncology. 37: 3084-3084. DOI: 10.1200/Jco.2019.37.15_Suppl.3084 |
0.502 |
|
| 2019 |
Ibraheem A, Olopade O, Huo D. Abstract P4-08-12: Comparative analyses of the prognostic value of oncotype and mammaprint using the National Cancer Database Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P4-08-12 |
0.435 |
|
| 2019 |
Hylton N, Symmans W, Yau C, Li W, Hatzis C, Isaacs C, Albain K, Chen Y, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, ... ... Olopade O, et al. Abstract P2-07-03: Refining neoadjuvant predictors of three year distant metastasis free survival: Integrating volume change as measured by MRI with residual cancer burden Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-P2-07-03 |
0.351 |
|
| 2019 |
Adedokun B, Odedina S, Ojengbede O, Ademola A, Ogundiran T, Huo D, Olopade O, Agwai I, Makumbi T, Ndom P, Gakwaya A. Abstract 624: A case control study of benign breast disease and breast cancer among indigenous African women Epidemiology. DOI: 10.1158/1538-7445.Sabcs18-624 |
0.501 |
|
| 2019 |
Ansari-Pour N, Pitt JJ, Dentro S, Fitzgerald D, Zheng Y, Yoshimatsu TF, Rajagopal P, Gruber A, Sanni A, Oluwasola O, Ajani M, Odetunde A, Popoola A, Falusi A, Ogundiran T, ... ... Olopade O, et al. Abstract LB-300: The life history of breast cancer in Nigerian women: Evidence for ethnic differences in tumor evolution based on whole-genome sequencing Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Lb-300 |
0.554 |
|
| 2019 |
Hattori M, Khramtsova G, Sveen L, Yoshimatsu T, Huo D, Olopade OI. Abstract 4040: PD-L1 expression level and CD8+/FoxP3+T cell ratio in breast cancer and prognosis Cancer Research. 79: 4040-4040. DOI: 10.1158/1538-7445.Am2019-4040 |
0.424 |
|
| 2019 |
Wolf DM, Yau C, Wulfkuhle J, Petricoin E, Brown-Swigart L, Hirst G, Asare S, Yee D, DeMichele A, Rugo H, Olopade O, Nanda R, Liu M, Esserman L, Veer Lvt. Abstract 2679: Integration of DNA repair deficiency and immune biomarkers to predict which early-stage triple-negative breast cancer patients are likely to respond to platinum-containing regimens vs. immunotherapy: The neoadjuvant I-SPY 2 trial Cancer Research. 79: 2679-2679. DOI: 10.1158/1538-7445.Am2019-2679 |
0.362 |
|
| 2018 |
Nielsen SM, Eccles DM, Romero IL, Al-Mulla F, Balmaña J, Biancolella M, Bslok R, Caligo MA, Calvello M, Capone GL, Cavalli P, Chan TLC, Claes KBM, Cortesi L, Couch FJ, ... ... Olopade OI, et al. Genetic Testing and Clinical Management Practices for Variants in Non-BRCA1/2 Breast (and Breast/Ovarian) Cancer Susceptibility Genes: An International Survey by the Evidence-Based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Clinical Working Group. Jco Precision Oncology. 2. PMID 31517176 DOI: 10.1200/PO.18.00091 |
0.396 |
|
| 2018 |
Beri N, Patrick-Miller LJ, Egleston BL, Hall MJ, Domchek SM, Daly MB, Ganschow P, Grana G, Olopade OI, Fetzer D, Brandt A, Chambers R, Clark DF, Forman A, Gaber R, et al. Preferences for in-person disclosure: Patients declining telephone disclosure characteristics and outcomes in the multi-center COGENT Study. Clinical Genetics. PMID 30417332 DOI: 10.1111/Cge.13474 |
0.339 |
|
| 2018 |
Ibraheem AF, Press DJ, Olopade OI, Huo D. Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: Who benefits from chemotherapy? Cancer. PMID 30387876 DOI: 10.1002/Cncr.31818 |
0.34 |
|
| 2018 |
Han YJ, Boatman SM, Zhang J, Du XC, Yeh AC, Zheng Y, Mueller J, Olopade OI. LncRNA BLAT1 is Upregulated in Basal-like Breast Cancer through Epigenetic Modifications. Scientific Reports. 8: 15572. PMID 30349062 DOI: 10.1038/S41598-018-33629-Y |
0.533 |
|
| 2018 |
Yan Y, Liu F, Han L, Zhao L, Chen J, Olopade OI, He M, Wei M. HIF-2α promotes conversion to a stem cell phenotype and induces chemoresistance in breast cancer cells by activating Wnt and Notch pathways. Journal of Experimental & Clinical Cancer Research : Cr. 37: 256. PMID 30340507 DOI: 10.1186/S13046-018-0925-X |
0.426 |
|
| 2018 |
Pitt JJ, Riester M, Zheng Y, Yoshimatsu TF, Sanni A, Oluwasola O, Veloso A, Labrot E, Wang S, Odetunde A, Ademola A, Okedere B, Mahan S, Leary R, Macomber M, ... ... Olopade OI, et al. Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features. Nature Communications. 9: 4181. PMID 30327465 DOI: 10.1038/S41467-018-06616-0 |
0.559 |
|
| 2018 |
Qian F, Wang S, Mitchell J, McGuffog L, Barrowdale D, Leslie G, Oosterwijk JC, Chung WK, Evans DG, Engel C, Kast K, Aalfs CM, Adank MA, Adlard J, Agnarsson BA, ... ... Olopade OI, et al. Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. Journal of the National Cancer Institute. PMID 30312457 DOI: 10.1093/jnci/djy132 |
0.415 |
|
| 2018 |
Pitt JJ, Zheng Y, Olopade OI. Genetic Ancestry May Influence the Evolutionary Trajectory of Cancers. Cancer Cell. 34: 529-530. PMID 30300575 DOI: 10.1016/J.Ccell.2018.09.006 |
0.417 |
|
| 2018 |
Odedina SO, Ajayi IO, Adeniji-Sofoluwe A, Morhason-Bello IO, Huo D, Olopade OI, Ojengbede OA. A longitudinal study of the prevalence and characteristics of breast disorders detected by clinical breast examination during pregnancy and six months postpartum in Ibadan, Southwestern Nigeria. Bmc Women's Health. 18: 152. PMID 30231883 DOI: 10.1186/S12905-018-0647-4 |
0.5 |
|
| 2018 |
Guindalini RS, Zheng Y, Abe H, Whitaker K, Yoshimatsu TF, Walsh T, Schacht D, Kulkarni K, Sheth D, Verp MS, Bradbury AR, Churpek J, Obeid E, Mueller J, Khramtsova GF, ... ... Olopade OI, et al. Intensive surveillance with bi-annual dynamic contrast-enhanced magnetic resonance imaging downstages breast cancer in BRCA1 mutation carriers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30154229 DOI: 10.1158/1078-0432.Ccr-18-0200 |
0.528 |
|
| 2018 |
Zheng Y, Walsh T, Gulsuner S, Casadei S, Lee MK, Ogundiran TO, Ademola A, Falusi AG, Adebamowo CA, Oluwasola AO, Adeoye A, Odetunde A, Babalola CP, Ojengbede OA, Odedina S, ... ... Olopade OI, et al. Inherited Breast Cancer in Nigerian Women. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2018783977. PMID 30130155 DOI: 10.1200/Jco.2018.78.3977 |
0.582 |
|
| 2018 |
Adejumo P, Aniagwu T, Oluwatosin A, Fagbenle O, Ajayi O, Ogungbade D, Oluwamotemi A, Olatoye-Wahab F, Oni A, Olajide O, Adedokun B, Ogundiran T, Olopade O. Knowledge of Genetic Counseling Among Patients With Breast Cancer and Their Relatives at a Nigerian Teaching Hospital. Journal of Global Oncology. 4: 1-8. PMID 30084716 DOI: 10.1200/Jgo.17.00158 |
0.547 |
|
| 2018 |
Lu Y, Beeghly-Fadiel A, Wu L, Guo X, Li B, Schildkraut JM, Im HK, Chen YA, Permuth JB, Reid BM, Teer JK, Moysich KB, Andrulis IL, Anton-Culver H, Arun BK, ... ... Olopade OI, et al. A transcriptome-wide association study among 97,898 women to identify candidate susceptibility genes for epithelial ovarian cancer risk. Cancer Research. PMID 30054336 DOI: 10.1158/0008-5472.Can-18-0951 |
0.37 |
|
| 2018 |
McWilliams RR, Wieben ED, Chaffee KG, Antwi SO, Raskin L, Olopade OI, Li D, Highsmith WE, Colon-Otero G, Khanna LG, Permuth JB, Olson JE, Frucht H, Genkinger JM, Zheng W, et al. CDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 30038052 DOI: 10.1158/1055-9965.Epi-17-1065 |
0.414 |
|
| 2018 |
Nielsen SM, De Simone LM, Olopade OI. Cancer Susceptibility Genetic Testing in a High-Risk Cohort of Urban Ashkenazi Jewish Individuals. Journal of Genetic Counseling. PMID 29946849 DOI: 10.1007/S10897-018-0269-X |
0.43 |
|
| 2018 |
Wu L, Shi W, Long J, Guo X, Michailidou K, Beesley J, Bolla MK, Shu XO, Lu Y, Cai Q, Al-Ejeh F, Rozali E, Wang Q, Dennis J, Li B, ... ... Olopade OI, et al. A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nature Genetics. PMID 29915430 DOI: 10.1038/S41588-018-0132-X |
0.53 |
|
| 2018 |
Scannell Bryan M, Argos M, Andrulis IL, Hopper JL, Chang-Claude J, Malone KE, John EM, Gammon MD, Daly MB, Terry MB, Buys SS, Huo D, Olopade OI, Genkinger JM, Whittemore AS, et al. Germline variation and breast cancer incidence: A gene-based association study and whole-genome prediction of early onset breast cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 29898891 DOI: 10.1158/1055-9965.Epi-17-1185 |
0.459 |
|
| 2018 |
Wang S, Huo D, Ogundiran TO, Ojengbede O, Zheng W, Nathanson KL, Nemesure B, Ambs S, Olopade OI, Zheng Y. Genetic variation in the Hippo pathway and breast cancer risk in women of African ancestry. Molecular Carcinogenesis. PMID 29873413 DOI: 10.1002/Mc.22845 |
0.547 |
|
| 2018 |
Debiasi M, Polanczyk CA, Ziegelmann P, Barrios C, Cao H, Dignam JJ, Goss P, Bychkovsky B, Finkelstein DM, Guindalini RS, Filho P, Albuquerque C, Reinert T, de Azambuja E, Olopade O. Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis. Frontiers in Oncology. 8: 156. PMID 29872641 DOI: 10.3389/Fonc.2018.00156 |
0.45 |
|
| 2018 |
Wang S, Ogundiran TO, Ademola A, Oluwasola OA, Adeoye AO, Sofoluwe A, Morhason-Bello I, Odedina SO, Agwai I, Adebamowo C, Obajimi M, Ojengbede O, Olopade OI, Huo D. Development of a Breast Cancer Risk Prediction Model for Women in Nigeria. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 29678902 DOI: 10.1158/1055-9965.Epi-17-1128 |
0.491 |
|
| 2018 |
Kim SJ, Huzarski T, Gronwald J, Singer CF, Møller P, Lynch HT, Armel S, Karlan BY, Foulkes WD, Neuhausen SL, Senter L, Eisen A, Eng C, Panchal S, Pal T, ... Olopade O, et al. Prospective evaluation of body size and breast cancer risk among BRCA1 and BRCA2 mutation carriers. International Journal of Epidemiology. PMID 29547931 DOI: 10.1093/Ije/Dyy039 |
0.521 |
|
| 2018 |
Huo D, Perou CM, Olopade OI. Reported Biologic Differences in Breast Cancer by Race Due to Disparities in Screening-Reply. Jama Oncology. PMID 29543936 DOI: 10.1001/Jamaoncol.2017.5909 |
0.506 |
|
| 2018 |
Bradbury AR, Patrick-Miller LJ, Egleston BL, Hall MJ, Domchek SM, Daly MB, Ganschow P, Grana G, Olopade OI, Fetzer D, Brandt A, Chambers R, Clark DF, Forman A, Gaber R, et al. Randomized Noninferiority Trial of Telephone vs In-Person Disclosure of Germline Cancer Genetic Test Results. Journal of the National Cancer Institute. PMID 29490071 DOI: 10.1093/Jnci/Djy015 |
0.361 |
|
| 2018 |
Rebbeck TR, Friebel TM, Friedman E, Hamann U, Huo D, Kwong A, Olah E, Olopade OI, Solano AR, Teo SH, Thomassen M, Weitzel JN, Chan TL, Couch FJ, Goldgar DE, et al. Mutational Spectrum in a Worldwide Study of 29,700 Families with BRCA1 or BRCA2 Mutations. Human Mutation. PMID 29446198 DOI: 10.1002/Humu.23406 |
0.354 |
|
| 2018 |
West AH, Blazer KR, Stoll J, Jones M, Weipert CM, Nielsen SM, Kupfer SS, Weitzel JN, Olopade OI. Clinical interpretation of pathogenic ATM and CHEK2 variants on multigene panel tests: navigating moderate risk. Familial Cancer. PMID 29445900 DOI: 10.1007/S10689-018-0070-X |
0.492 |
|
| 2018 |
Lammert J, Lubinski J, Gronwald J, Huzarski T, Armel S, Eisen A, Meschino WS, Lynch HT, Snyder C, Eng C, Olopade OI, Ginsburg O, Foulkes WD, Elser C, Cohen SA, et al. Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment. PMID 29404807 DOI: 10.1007/S10549-018-4694-1 |
0.531 |
|
| 2018 |
Kim D, Shivakumar M, Han S, Sinclair MS, Lee Y, Zheng Y, Olopade OI, Kim D, Lee Y. Population-dependent Intron Retention and DNA Methylation in Breast Cancer. Molecular Cancer Research : McR. PMID 29330282 DOI: 10.1158/1541-7786.Mcr-17-0227 |
0.382 |
|
| 2018 |
Wang S, Qian F, Zheng Y, Ogundiran T, Ojengbede O, Zheng W, Blot W, Nathanson KL, Hennis A, Nemesure B, Ambs S, Olopade OI, Huo D. Genetic variants demonstrating flip-flop phenomenon and breast cancer risk prediction among women of African ancestry. Breast Cancer Research and Treatment. PMID 29302764 DOI: 10.1007/S10549-017-4638-1 |
0.461 |
|
| 2018 |
Ngene SO, Adedokun B, Adejumo P, Olopade O. Breast Cancer Genetics Knowledge and Testing Intentions among Nigerian Professional Women Journal of Genetic Counseling. 27: 863-873. PMID 29260484 DOI: 10.1007/S10897-017-0194-4 |
0.504 |
|
| 2018 |
Troester MA, Sun X, Allott EH, Geradts J, Cohen SM, Tse CK, Kirk EL, Thorne LB, Mathews M, Li Y, Hu Z, Robinson WR, Hoadley KA, Olopade OI, Reeder-Hayes KE, et al. Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study. Journal of the National Cancer Institute. 110. PMID 28859290 DOI: 10.1093/Jnci/Djx135 |
0.482 |
|
| 2018 |
Adedokun B, Zheng Y, Ndom P, Gakwaya A, Makumbi T, Sallam A, Olopade O, Huo D. Prevalence and Spectrum of Breast Cancer Inherited Mutations in Uganda and Cameroon Women Journal of Global Oncology. 4. DOI: 10.1200/Jgo.18.60600 |
0.562 |
|
| 2018 |
Odedina SO, Ajayi IO, Morhason-Bello IO, Adeniji-Sofoluwe A, Huo D, Olopade OI, Ojengbede O. Profile of Women With Breast Disorders in Pregnancy and Lactation and Additional Investigation Uptake Journal of Global Oncology. 4. DOI: 10.1200/Jgo.18.10340 |
0.424 |
|
| 2018 |
Hamlish T, Moton ZN, Zhang Z, Sohmer D, Olopade OI, Johnson D, Hong S. Identifying challenges to breast cancer care coordination at urban community-based primary care clinics. Journal of Clinical Oncology. 36: 83-83. DOI: 10.1200/Jco.2018.36.7_Suppl.83 |
0.424 |
|
| 2018 |
Leng J, Ibraheem AF, Sowunmi AC, Ademola AF, Ntekim A, Olopade OI. Attitudes of breast cancer patients and oncology staff towards randomized clinical trials in southwest Nigeria. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.E18663 |
0.448 |
|
| 2018 |
Bradbury AR, Gaieski JB, Egleston BL, Patrick-Miller LJ, Chung W, Olopade OI, Maxwell KN, Walser S, Fetzer D, Brower J, Brandt AC, Clark D, DiGiovanni L, Long JM, Powers J, et al. Interest in and outcomes with web-based education for return of genetic research results for inherited susceptibility to breast cancer. Journal of Clinical Oncology. 36: 1531-1531. DOI: 10.1200/Jco.2018.36.15_Suppl.1531 |
0.366 |
|
| 2018 |
Shang L, Jaskowiak NT, Hedeker D, Olopade OI, Huo D. Pre- and post-treatment body weight and prognosis in a multiethnic cohort of breast cancer patients. Journal of Clinical Oncology. 36: 1501-1501. DOI: 10.1200/Jco.2018.36.15_Suppl.1501 |
0.469 |
|
| 2018 |
Choudhury N, Evans P, Ingle JN, Mayer IA, Morrow PKH, Storniolo AM, Forero-Torres A, Poznak CHV, Merkel DE, Dees EC, Fleming GF, Hahn OM, Hoffman PC, Olopade OI, Cox N, et al. Clinical evaluation of germline polymorphisms (SNPs) associated with disease response to capecitabine in metastatic breast cancer (MBC) (TBCRC 015). Journal of Clinical Oncology. 36: 1071-1071. DOI: 10.1200/Jco.2018.36.15_Suppl.1071 |
0.395 |
|
| 2018 |
Olopade OI. Abstract IA19: Homologous recombination repair deficiency and breast cancer progression in high-risk populations Molecular Cancer Research. 16. DOI: 10.1158/1557-3125.Advbc17-Ia19 |
0.576 |
|
| 2018 |
Amico A, Fang R, Raoul A, Wroblewski K, Nielsen S, Weipert C, Abe H, Sheth D, Romero I, Kulkarni K, Schacht D, Patrick-Miller L, Verp M, Bradbury A, Hlubocky F, ... Olopade O, et al. Abstract P5-19-04: Psychosocial impact of a multi-modality surveillance program for women at high-risk for breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P5-19-04 |
0.427 |
|
| 2018 |
Whitaker K, Guindalini R, Abe H, Sheeth D, Huo D, Hong S, Churpek J, Verp M, Obeid E, Zheng Y, Amico A, Yoshimatsu T, Olopade O. Abstract P4-02-10: Breast cancer surveillance in high-risk women with dynamic contrast-enhanced magnetic resonance imaging every 6 months: Results from a single institution study Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P4-02-10 |
0.49 |
|
| 2018 |
Whitaker K, Abe H, Sheth D, Huo D, Yoshimatsu T, Verp M, Zheng Y, Karczmar G, Guindalini R, Olopade O. Abstract P4-02-01: Recall rates during breast cancer surveillance in high-risk women with dynamic contrast-enhanced magnetic resonance imaging every 6 months: Results from a single institution study Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P4-02-01 |
0.335 |
|
| 2018 |
Wang S, Pitt JJ, Zheng Y, Yoshimatsu TF, Gao G, Riester M, Sanni A, Oluwasola O, Fitzgerald D, Ogundiran T, Babalola C, Popoola A, Falusi A, Winckler W, Obafunwa J, ... ... Olopade OI, et al. Abstract 287: Germline variants and somatic mutation signatures in breast cancer across populations of African and European ancestry Cancer Research. 78: 287-287. DOI: 10.1158/1538-7445.Am2018-287 |
0.526 |
|
| 2018 |
Han YJ, Zhang J, Mason JM, Yoshimatsu TF, Du X, Hurley I, Kim DE, Anantharaman A, Brunet LP, Prat A, Kwon J, Prasanth KV, Olopade OI. Abstract 1373: Circular RNAs generated from the BRCA1 pseudogene regulates the DNA damage response through SERBP1 RNA-binding protein Cancer Research. 78: 1373-1373. DOI: 10.1158/1538-7445.Am2018-1373 |
0.347 |
|
| 2017 |
Wang S, Zheng Y, Ogundiran TO, Ojengbede O, Zheng W, Nathanson KL, Nemesure B, Ambs S, Olopade OI, Huo D. Association of Pancreatic Cancer Susceptibility Variants with Risk of Breast Cancer in Women of European and African Ancestry. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 29254938 DOI: 10.1158/1055-9965.Epi-17-0755 |
0.554 |
|
| 2017 |
Michailidou K, Lindström S, Dennis J, Beesley J, Hui S, Kar S, Lemaçon A, Soucy P, Glubb D, Rostamianfar A, Bolla MK, Wang Q, Tyrer J, Dicks E, Lee A, ... ... Olopade OI, et al. Association analysis identifies 65 new breast cancer risk loci. Nature. PMID 29059683 DOI: 10.1038/Nature24284 |
0.553 |
|
| 2017 |
Milne RL, Kuchenbaecker KB, Michailidou K, Beesley J, Kar S, Lindström S, Hui S, Lemaçon A, Soucy P, Dennis J, Jiang X, Rostamianfar A, Finucane H, Bolla MK, McGuffog L, ... ... Olopade OI, et al. Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics. PMID 29058716 DOI: 10.1038/Ng.3785 |
0.554 |
|
| 2017 |
Gao G, Pierce BL, Olopade OI, Im HK, Huo D. Trans-ethnic predicted expression genome-wide association analysis identifies a gene for estrogen receptor-negative breast cancer. Plos Genetics. 13: e1006727. PMID 28957356 DOI: 10.1371/Journal.Pgen.1006727 |
0.541 |
|
| 2017 |
Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, ... ... Olopade O, et al. DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. Npj Breast Cancer. 3: 31. PMID 28948212 DOI: 10.1038/s41523-017-0025-7 |
0.304 |
|
| 2017 |
Felix GES, Zheng Y, Olopade OI. Mutations in context: implications of BRCA testing in diverse populations. Familial Cancer. PMID 28918466 DOI: 10.1007/S10689-017-0038-2 |
0.461 |
|
| 2017 |
Wang S, Huo D, Kupfer S, Alleyne D, Ogundiran TO, Ojengbede O, Zheng W, Nathanson KL, Nemesure B, Ambs S, Olopade OI, Zheng Y. Genetic variation in the Vitamin D related pathway and breast cancer risk in women of African ancestry in the Root Consortium. International Journal of Cancer. PMID 28891071 DOI: 10.1002/Ijc.31038 |
0.455 |
|
| 2017 |
Vanderpuye VDNK, Olopade OI, Huo D. Pilot Survey of Breast Cancer Management in Sub-Saharan Africa. Journal of Global Oncology. 3: 194-200. PMID 28717760 DOI: 10.1200/Jgo.2016.004945 |
0.465 |
|
| 2017 |
Murphy ME, Liu S, Yao S, Huo D, Liu Q, Dolfi SC, Hirshfield KM, Hong CC, Hu Q, Olshan AF, Ogundiran TO, Adebamowo C, Domchek SM, Nathanson KL, Nemesure B, ... ... Olopade OI, et al. A functionally significant SNP in TP53 and breast cancer risk in African-American women. Npj Breast Cancer. 3: 5. PMID 28649645 DOI: 10.1038/s41523-017-0007-9 |
0.439 |
|
| 2017 |
Wang S, Huo D, Ogundiran TO, Ojengbede O, Zheng W, Nathanson KL, Nemesure B, Ambs S, Olopade OI, Zheng Y. Association of breast cancer risk and the mTOR pathway in women of African ancestry in "The Root" Consortium. Carcinogenesis. PMID 28582508 DOI: 10.1093/Carcin/Bgx055 |
0.556 |
|
| 2017 |
Huo D, Hu H, Rhie SK, Gamazon ER, Cherniack AD, Liu J, Yoshimatsu TF, Pitt JJ, Hoadley KA, Troester M, Ru Y, Lichtenberg T, Sturtz LA, Shelley CS, Benz CC, ... ... Olopade OI, et al. Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas. Jama Oncology. PMID 28472234 DOI: 10.1001/Jamaoncol.2017.0595 |
0.528 |
|
| 2017 |
Lecarpentier J, Silvestri V, Kuchenbaecker KB, Barrowdale D, Dennis J, McGuffog L, Soucy P, Leslie G, Rizzolo P, Navazio AS, Valentini V, Zelli V, Lee A, Amin Al Olama A, Tyrer JP, ... ... Olopade OI, et al. Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016694935. PMID 28448241 DOI: 10.1200/Jco.2016.69.4935 |
0.511 |
|
| 2017 |
Feng Y, Rhie SK, Huo D, Ruiz-Narvaez EA, Haddad SA, Ambrosone CB, John EM, Bernstein L, Zheng W, Hu JJ, Ziegler RG, Nyante S, Bandera EV, Ingles SA, Press MF, ... ... Olopade OI, et al. Characterizing Genetic Susceptibility to Breast Cancer in Women of African Ancestry. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 28377418 DOI: 10.1158/1055-9965.Epi-16-0567 |
0.496 |
|
| 2017 |
Chiyoda T, Hart PC, Eckert MA, McGregor SM, Lastra RR, Hamamoto R, Nakamura Y, Yamada SD, Olopade OI, Lengyel E, Romero IL. Loss of BRCA1 in the cells of origin of ovarian cancer induces glycolysis: A window of opportunity for ovarian cancer chemoprevention. Cancer Prevention Research (Philadelphia, Pa.). PMID 28264838 DOI: 10.1158/1940-6207.Capr-16-0281 |
0.485 |
|
| 2017 |
Medved M, Li H, Abe H, Sheth D, Newstead GM, Olopade OI, Giger ML, Karczmar GS. Fast bilateral breast coverage with high spectral and spatial resolution (HiSS) MRI at 3T. Journal of Magnetic Resonance Imaging : Jmri. PMID 28263425 DOI: 10.1002/Jmri.25658 |
0.428 |
|
| 2017 |
Daly B, Olopade OI, Hou N, Yao K, Winchester DJ, Huo D. Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States. Jama Oncology. PMID 28152150 DOI: 10.1001/Jamaoncol.2016.6380 |
0.442 |
|
| 2017 |
Hall MJ, Olopade OI, Daly MB, Kupfer S. Germline ATM mutations in families with early-onset and familial gastroesophageal and colorectal cancers. Journal of Clinical Oncology. 35: 11-11. DOI: 10.1200/Jco.2017.35.4_Suppl.11 |
0.479 |
|
| 2017 |
Fatiregun OA, Olopade OI, Popoola A. Clinical trials: A key tool in improving breast cancer survival in Nigeria. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.E18198 |
0.495 |
|
| 2017 |
Ibraheem AF, Awolude OA, Habeebu MM, Sowunmi AC, Olaniyi PA, Olopade OI, Polite BN. Formal assessment of teamwork among cancer health care professionals in 3 large tertiary centers in Nigeria. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.E18126 |
0.396 |
|
| 2017 |
Olopade OI, Nielsen S, Wang S, Bernhisel R, Brown K, Cox HC, Cummings S, Rosenthal ET, Saam J, Lancaster JM, Huo D. Ancestry-based differences in hereditary cancer genetic testing. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.E13107 |
0.472 |
|
| 2017 |
Lee KM, Wang S, Huo D, Ogundiran TO, Ojengbede O, Zheng W, Nathanson KL, Nemesure B, Ambs S, Zheng Y, Olopade OI. Association of breast cancer risk in women of African ancestry with genetic variants in the TET-related DNA demethylation pathway. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.E13015 |
0.464 |
|
| 2017 |
Felix GES, Zheng Y, Guindalini RSC, Machado-Lopes TMB, Zhang J, Côrtes J, Oliveira PC, Santos IS, Bomfim T, Garicochea B, Toralles MB, Abe-Sandes K, Nascimento ILO, King M, Walsh T, ... Olopade OI, et al. BROCA gene panel testing in African descendants from northeastern Brazil: Genetic susceptibility profile of an admixed population. Journal of Clinical Oncology. 35: 1572-1572. DOI: 10.1200/Jco.2017.35.15_Suppl.1572 |
0.573 |
|
| 2017 |
Olopade O, Pitt J, Riester M, Odetunde A, Yoshimatsu T, Labrot E, Ademola A, Sanni A, Okedere B, Mahan S, Nwosu I, Leary R, Ajani M, Johnson R, Sveen E, et al. Abstract PD8-05: Comparative analysis of the genomic landscape of breast cancers from women of African and European ancestry Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-Pd8-05 |
0.442 |
|
| 2017 |
Wang S, Qian F, Zheng Y, Ogundiran T, Ojengbede O, Zheng W, Blot W, Nathanson K, Hennis A, Nemesure B, Ambs S, Olopade O, Huo D. Abstract P5-09-02: Breast cancer risk prediction using a polygenic risk score in women of African ancestry: Findings from GWAS in breast cancer in the African diaspora Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P5-09-02 |
0.409 |
|
| 2017 |
Huo D, Hu H, Rhie S, Gamazon E, Cherniack A, Liu J, Yoshimatsu T, Pitt J, Hoadley K, Troester M, Ru Y, Lichtenberg T, Sturtz L, Shelley C, Mills G, ... ... Olopade O, et al. Abstract P1-05-11: Comprehensive comparison of breast cancer molecular portraits by African and European ancestry in the cancer genome atlas Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P1-05-11 |
0.463 |
|
| 2017 |
Lawan A, Khramtsova G, Irabor D, Ajani M, Sveen L, Abdullah YM, Ebili HO, Saad U, Ogunbiyi JO, Olopade OI, Oluwasola AO. Abstract B07: Molecular characterization of colorectal cancer in West Africans Cancer Research. 77. DOI: 10.1158/1538-7445.Crc16-B07 |
0.398 |
|
| 2017 |
Kim D, Shivakumar M, Lee Y, Olopade O, Kim D, Lee Y. Abstract LB-003: Racial differences of intron retention and DNA methylation in breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-003 |
0.466 |
|
| 2017 |
Han YJ, Boatman SM, Zhang J, Yeh AC, Zheng Y, Olopade OI. Abstract 717: Diagnosis of basal like breast cancer using DNA methylation markers at the promoters of long noncoding RNAs Cancer Research. 77: 717-717. DOI: 10.1158/1538-7445.Am2017-717 |
0.424 |
|
| 2017 |
Karginova O, Weekley C, Raoul A, Alsayed A, Wu T, He C, Olopade OI. Abstract 3552: Selective inhibition of copper metabolism as a novel approach to treat triple-negative breast cancer Cancer Research. 77: 3552-3552. DOI: 10.1158/1538-7445.Am2017-3552 |
0.367 |
|
| 2017 |
Swoboda A, Khramtsova G, Sveen L, Khramtsov A, Nanda R, Olopade O. Abstract 2950: Biomarkers of immune infiltration for multiplex immunofluorescence in breast cancer Cancer Research. 77: 2950-2950. DOI: 10.1158/1538-7445.Am2017-2950 |
0.444 |
|
| 2017 |
Wang S, Zheng Y, Ogundiran TO, Ojengbede O, Zheng W, Nathanson KL, Nemesure B, Ambs S, Huo D, Olopade OI. Abstract 1312: Genetic variation in the Hippo pathway and breast cancer risk in women of African ancestry in the ROOT Consortium Epidemiology. 77: 1312-1312. DOI: 10.1158/1538-7445.Am2017-1312 |
0.502 |
|
| 2016 |
Huo D, Feng Y, Haddad S, Zheng Y, Yao S, Han YJ, Ogundiran TO, Adebamowo C, Ojengbede O, Falusi AG, Zheng W, Blot W, Cai Q, Signorello L, John EM, ... ... Olopade OI, et al. Genome-wide association studies in women of African ancestry identified 3q26.21 as a novel susceptibility locus for oestrogen receptor negative breast cancer. Human Molecular Genetics. 25: 4835-4846. PMID 28171663 DOI: 10.1093/Hmg/Ddw305 |
0.549 |
|
| 2016 |
Powers-James C, Alvarez AL, Milbury K, Adan F, Lopez G, Cohen L, Delgado-Guay M, Olopade OI, Curlin FA. The influence of spirituality and religiosity on the personal use and practice patterns with complementary and alternative medicine (CAM): A national survey of US oncologists. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 34: 248. PMID 28156545 DOI: 10.1200/Jco.2016.34.26_Suppl.248 |
0.318 |
|
| 2016 |
Rebbeck TR, Friebel TM, Mitra N, Wan F, Chen S, Andrulis IL, Apostolou P, Arnold N, Arun BK, Barrowdale D, Benitez J, Berger R, Berthet P, Borg A, Buys SS, ... ... Olopade OI, et al. Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Research : Bcr. 18: 112. PMID 27836010 DOI: 10.1186/S13058-016-0768-3 |
0.351 |
|
| 2016 |
Han YJ, Zhang J, Zheng Y, Huo D, Olopade OI. Genetic and Epigenetic Regulation of TOX3 Expression in Breast Cancer. Plos One. 11: e0165559. PMID 27806084 DOI: 10.1371/Journal.Pone.0165559 |
0.513 |
|
| 2016 |
Hamdi Y, Soucy P, Kuchenbaeker KB, Pastinen T, Droit A, Lemaçon A, Adlard J, Aittomäki K, Andrulis IL, Arason A, Arnold N, Arun BK, Azzollini J, Bane A, Barjhoux L, ... ... Olopade OI, et al. Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment. PMID 27796716 DOI: 10.1007/S10549-016-4018-2 |
0.563 |
|
| 2016 |
Baretta Z, Mocellin S, Goldin E, Olopade OI, Huo D. Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis. Medicine. 95: e4975. PMID 27749552 DOI: 10.1097/Md.0000000000004975 |
0.547 |
|
| 2016 |
Catucci I, Casadei S, Ding YC, Volorio S, Ficarazzi F, Falanga A, Marchetti M, Tondini C, Franchi M, Adamson A, Mandell J, Walsh T, Olopade OI, Manoukian S, Radice P, et al. Haplotype analyses of the c.1027C>T and c.2167_2168delAT recurrent truncating mutations in the breast cancer-predisposing gene PALB2. Breast Cancer Research and Treatment. PMID 27624329 DOI: 10.1007/S10549-016-3981-Y |
0.491 |
|
| 2016 |
Lawrenson K, Kar S, McCue K, Kuchenbaeker K, Michailidou K, Tyrer J, Beesley J, Ramus SJ, Li Q, Delgado MK, Lee JM, Aittomäki K, Andrulis IL, Anton-Culver H, Arndt V, ... ... Olopade OI, et al. Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nature Communications. 7: 12675. PMID 27601076 DOI: 10.1038/ncomms12675 |
0.351 |
|
| 2016 |
Huo D, Feng Y, Haddad S, Zheng Y, Yao S, Han YJ, Ogundiran TO, Adebamowo C, Ojengbede O, Falusi AG, Zheng W, Blot W, Cai Q, Signorello L, John EM, ... ... Olopade OI, et al. Genome-wide Association Studies in Women of African Ancestry Identified 3q26.21 as a Novel Susceptibility Locus for Estrogen Receptor Negative Breast Cancer. Human Molecular Genetics. PMID 27594435 DOI: 10.1093/hmg/ddw305 |
0.462 |
|
| 2016 |
Vigorito E, Kuchenbaecker KB, Beesley J, Adlard J, Agnarsson BA, Andrulis IL, Arun BK, Barjhoux L, Belotti M, Benitez J, Berger A, Bojesen A, Bonanni B, Brewer C, Caldes T, ... ... Olopade OI, et al. Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Plos One. 11: e0158801. PMID 27463617 DOI: 10.1371/Journal.Pone.0158801 |
0.475 |
|
| 2016 |
Zeng C, Guo X, Long J, Kuchenbaecker KB, Droit A, Michailidou K, Ghoussaini M, Kar S, Freeman A, Hopper JL, Milne RL, Bolla MK, Wang Q, Dennis J, Agata S, ... ... Olopade OI, et al. Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Research : Bcr. 18: 64. PMID 27459855 DOI: 10.1186/S13058-016-0718-0 |
0.467 |
|
| 2016 |
Huo D, Clayton WM, Yoshimatsu TF, Chen J, Olopade OI. Identification of a circulating MicroRNA signature to distinguish recurrence in breast cancer patients. Oncotarget. PMID 27409424 DOI: 10.18632/Oncotarget.10485 |
0.448 |
|
| 2016 |
Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, et al. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. The New England Journal of Medicine. 375: 23-34. PMID 27406347 DOI: 10.1056/Nejmoa1513749 |
0.522 |
|
| 2016 |
Qian F, Feng Y, Zheng Y, Ogundiran TO, Ojengbede O, Zheng W, Blot W, Ambrosone CB, John EM, Bernstein L, Hu JJ, Ziegler RG, Nyante S, Bandera EV, Ingles SA, ... ... Olopade OI, et al. Genetic variants in microRNA and microRNA biogenesis pathway genes and breast cancer risk among women of African ancestry. Human Genetics. PMID 27380242 DOI: 10.1007/S00439-016-1707-1 |
0.442 |
|
| 2016 |
Couch FJ, Kuchenbaecker KB, Michailidou K, Mendoza-Fandino GA, Nord S, Lilyquist J, Olswold C, Hallberg E, Agata S, Ahsan H, Aittomäki K, Ambrosone C, Andrulis IL, Anton-Culver H, Arndt V, ... ... Olopade OI, et al. Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications. 7: 11375. PMID 27117709 DOI: 10.1038/Ncomms11375 |
0.531 |
|
| 2016 |
Fackenthal JD, Yoshimatsu T, Zhang B, de Garibay GR, Colombo M, De Vecchi G, Ayoub SC, Lal K, Olopade OI, Vega A, Santamariña M, Blanco A, Wappenschmidt B, Becker A, Houdayer C, et al. Naturally occurring BRCA2 alternative mRNA splicing events in clinically relevant samples. Journal of Medical Genetics. PMID 27060066 DOI: 10.1136/Jmedgenet-2015-103570 |
0.465 |
|
| 2016 |
Guindalini RS, Song A, Fackenthal JD, Olopade OI, Huo D. Genetic anticipation in BRCA1/BRCA2 families after controlling for ascertainment bias and cohort effect. Cancer. PMID 26992017 DOI: 10.1200/Jco.2014.32.15_Suppl.1550 |
0.547 |
|
| 2016 |
Polite BN, Cipriano-Steffens T, Hlubocky F, Dignam J, Ray M, Smith D, Undevia S, Sprague E, Olopade O, Daugherty C, Fitchett G, Gehlert S. An Evaluation of Psychosocial and Religious Belief Differences in a Diverse Racial and Socioeconomic Urban Cancer Population. Journal of Racial and Ethnic Health Disparities. PMID 26983622 DOI: 10.1007/S40615-016-0211-6 |
0.456 |
|
| 2016 |
Saha P, Amico AL, Olopade OI. Long-Term Disease-Free Survival in a Young Patient With Hormone Receptor-Positive Breast Cancer and Oligometastatic Disease in the Brain. Clinical Breast Cancer. PMID 26943988 DOI: 10.1016/J.Clbc.2016.02.013 |
0.405 |
|
| 2016 |
Dunning AM, Michailidou K, Kuchenbaecker KB, Thompson D, French JD, Beesley J, Healey CS, Kar S, Pooley KA, Lopez-Knowles E, Dicks E, Barrowdale D, Sinnott-Armstrong NA, Sallari RC, Hillman KM, ... ... Olopade OI, et al. Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics. PMID 26928228 DOI: 10.1038/Ng.3521 |
0.411 |
|
| 2016 |
Nielsen SM, White MG, Hong S, Aschebrook-Kilfoy B, Kaplan EL, Angelos P, Kulkarni SA, Olopade OI, Grogan RH. The Breast-Thyroid Cancer Link: A Systematic Review and Meta-analysis. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 25: 231-8. PMID 26908594 DOI: 10.1158/1055-9965.Epi-15-0833 |
0.534 |
|
| 2016 |
Ngwa W, Ngoma T, Zietman A, Mayr N, Elzawawy A, Winningham TA, Balogun O, Enwerem-Bromson N, Ntizimira C, Olopade OI, Oluwole D, Odedina F, Williams M, Flanigan J, Asana L, et al. Closing the Cancer Divide Through Ubuntu: Information and Communication Technology-Powered Models for Global Radiation Oncology. International Journal of Radiation Oncology, Biology, Physics. 94: 440-9. PMID 26867873 DOI: 10.1016/J.Ijrobp.2015.10.063 |
0.407 |
|
| 2016 |
Silvestri V, Barrowdale D, Mulligan AM, Neuhausen SL, Fox S, Karlan BY, Mitchell G, James P, Thull DL, Zorn KK, Carter NJ, Nathanson KL, Domchek SM, Rebbeck TR, Ramus SJ, ... ... Olopade OI, et al. Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research : Bcr. 18: 15. PMID 26857456 DOI: 10.1186/S13058-016-0671-Y |
0.522 |
|
| 2016 |
Ezewuiro O, Grushko TA, Kocherginsky M, Habis M, Hurteau JA, Mills KA, Hunn J, Olopade OI, Fleming GF, Romero IL. Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy. Plos One. 11: e0147145. PMID 26788855 DOI: 10.1371/Journal.Pone.0147145 |
0.321 |
|
| 2016 |
Meeks HD, Song H, Michailidou K, Bolla MK, Dennis J, Wang Q, Barrowdale D, Frost D, McGuffog L, Ellis S, Feng B, Buys SS, Hopper JL, Southey MC, ... ... Olopade OI, et al. BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. Journal of the National Cancer Institute. 108. PMID 26586665 DOI: 10.1093/Jnci/Djv315 |
0.535 |
|
| 2016 |
Bradbury AR, Patrick-Miller LJ, Egleston BL, Olopade OI, Hall MJ, Daly MB, Fleisher L, Grana G, Ganschow P, Fetzer D, Domchek SM. Patient-reported outcomes in a multicenter randomized study of in-person versus telephone disclosure of genetic test results for cancer susceptibility. Journal of Clinical Oncology. 34: 1502-1502. DOI: 10.1200/Jco.2016.34.15_Suppl.1502 |
0.364 |
|
| 2016 |
Olayiwola O, Ogundiran T, Hardeman A, Yoshimatsu T, Clayton W, Adeoye A, Ademola A, Ajani M, Khramtsova G, Grushko T, Huo D, Zheng Y, Parker J, Perou C, Olopade O. Abstract P6-04-05: Genotype-phenotype classification of triple negative breast cancers (TNBC) in women of African descent using the PAM50 NanoString platform and genomic data Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P6-04-05 |
0.434 |
|
| 2016 |
Olopade O, Odetunde A, Riester M, Yoshimatsu T, Labrot E, Ademola A, Sanni A, Okedere B, Mahan S, Nwosu I, Leary R, Ajani M, Johnson R, Sveen E, Zheng Y, et al. Abstract P6-03-17: Genomic landscape of breast cancers from women of African ancestry across the diaspora Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P6-03-17 |
0.486 |
|
| 2016 |
Han YJ, Zhang J, Mason JM, Prat A, Yoshimatsu T, Perou CM, Kwon J, Kannanganattu P, Olopade OI. Abstract 994: Long noncoding RNAs generated from the BRCA1 pseudogene regulate genomic instability and homologous recombination repair Cancer Research. 76: 994-994. DOI: 10.1158/1538-7445.Am2016-994 |
0.423 |
|
| 2016 |
Wolf DM, Yau C, Brown-Swigart L, Hirst G, Buxton M, Paoloni M, Investigators IT, Olopade O, Michele AD, Symmans F, Rugo H, Berry D, Esserman L, Veer Lv‘. Abstract 859: Gene and pathway differences between MammaPrint High1/High2 risk classes: results from the I-SPY 2 TRIAL in breast cancer Cancer Research. 76: 859-859. DOI: 10.1158/1538-7445.Am2016-859 |
0.423 |
|
| 2016 |
Wolf DM, Yau C, Sanil A, Brown-Swigart L, Hirst G, Buxton M, Paoloni M, Investigators IT, Olopade O, Rugo H, Michele AD, Symmans F, Berry D, Esserman L, Veer Lv‘. Abstract 858: Combining sensitivity markers to identify triple-negative breast cancer patients most responsive to veliparib/carboplatin: results from the I-SPY 2 TRIAL Cancer Research. 76: 858-858. DOI: 10.1158/1538-7445.Am2016-858 |
0.404 |
|
| 2016 |
Pitt JJ, Yoshimatsu TF, Zheng Y, Grundstad J, Tuteja J, Wang J, Odetunde A, Khramtsova G, Clayton W, Ademola A, Ogundiran TO, Adeniji-Sofoluwe AT, Obajimi M, Adeoye A, Babalola C, ... ... Olopade OI, et al. Abstract 4494: Whole genome sequencing reveals different patterns of mutational mechanisms in breast tumors between women of African and European descent Cancer Research. 76: 4494-4494. DOI: 10.1158/1538-7445.Am2016-4494 |
0.533 |
|
| 2016 |
Yeh AC, McGregor S, Li H, Ji Y, Zhu Y, Grushko T, Edwards A, Lui F, Zhang J, Niu Q, Zheng Y, Yoshimatsu T, Khramtsova G, Drukker K, Karczmar G, ... ... Olopade O, et al. Abstract 2633: Radiogenomics of breast cancer using DCE-MRI and gene expression profiling Cancer Research. 76: 2633-2633. DOI: 10.1158/1538-7445.Am2016-2633 |
0.473 |
|
| 2016 |
Wang S, Ogundiran T, Ademola A, Olayiwola OA, Adeoye A, Adeniji-Sofoluwe A, Morhason-Bello I, Odedina S, Agwai I, Adebamowo C, Obajimi M, Ojengbede O, Olopade OI, Huo D. Abstract 2590: Development and validation of a breast cancer risk prediction model for black women: findings from the Nigerian breast cancer study: Table 1 Epidemiology. 76: 2590-2590. DOI: 10.1158/1538-7445.Am2016-2590 |
0.54 |
|
| 2016 |
Nielsen SM, White MG, Hong S, Aschebrook-Kilfoy B, Kaplan EL, Angelos P, Kulkarni SA, Olopade OI, Grogan RH. The breast-thyroid cancer link: A systematic review and meta-analysis Cancer Epidemiology Biomarkers and Prevention. 25: 231-238. DOI: 10.1158/1055-9965.EPI-15-0833 |
0.374 |
|
| 2016 |
Solola J, Olopade O. Assessing perceptions of genetic risk and breast cancer of women
diagnosed and undiagnosed with breast cancer in Ibadan, Nigeria Annals of Global Health. 82: 559. DOI: 10.1016/J.AOGH.2016.04.504 |
0.462 |
|
| 2015 |
Churpek JE, Marquez R, Neistadt B, Claussen K, Lee MK, Churpek MM, Huo D, Weiner H, Bannerjee M, Godley LA, Le Beau MM, Pritchard CC, Walsh T, King MC, Olopade OI, et al. Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. Cancer. PMID 26641009 DOI: 10.1002/Cncr.29615 |
0.522 |
|
| 2015 |
Poli E, Zhang J, Nwachukwu C, Zheng Y, Adedokun B, Olopade OI, Han YJ. Molecular Subtype-Specific Expression of MicroRNA-29c in Breast Cancer Is Associated with CpG Dinucleotide Methylation of the Promoter. Plos One. 10: e0142224. PMID 26539832 DOI: 10.1371/Journal.Pone.0142224 |
0.437 |
|
| 2015 |
Guindalini RS, Win AK, Gulden C, Lindor NM, Newcomb PA, Haile RW, Raymond V, Stoffel E, Hall M, Llor X, Ukaegbu CI, Solomon I, Weitzel J, Kalady M, Blanco A, ... ... Olopade OI, et al. Mutation Spectrum and Risk of Colorectal Cancer in African American Families with Lynch Syndrome. Gastroenterology. 149: 1446-53. PMID 26248088 DOI: 10.1053/J.Gastro.2015.07.052 |
0.414 |
|
| 2015 |
Metcalfe K, Lynch HT, Foulkes WD, Tung N, Kim-Sing C, Olopade OI, Eisen A, Rosen B, Snyder C, Gershman S, Sun P, Narod SA. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. Jama Oncology. 1: 306-13. PMID 26181175 DOI: 10.1001/Jamaoncol.2015.0658 |
0.569 |
|
| 2015 |
Daly B, Olopade OI. A perfect storm: How tumor biology, genomics, and health care delivery patterns collide to create a racial survival disparity in breast cancer and proposed interventions for change. Ca: a Cancer Journal For Clinicians. 65: 221-38. PMID 25960198 DOI: 10.3322/Caac.21271 |
0.527 |
|
| 2015 |
Hollestelle A, van der Baan FH, Berchuck A, Johnatty SE, Aben KK, Agnarsson BA, Aittomäki K, Alducci E, Andrulis IL, Anton-Culver H, Antonenkova NN, Antoniou AC, Apicella C, Arndt V, ... ... Olopade OI, et al. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology. PMID 25940428 DOI: 10.1016/J.Ygyno.2015.04.034 |
0.517 |
|
| 2015 |
Blein S, Bardel C, Danjean V, McGuffog L, Healey S, Barrowdale D, Lee A, Dennis J, Kuchenbaecker KB, Soucy P, Terry MB, Chung WK, Goldgar DE, Buys SS, ... ... Olopade OI, et al. An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research : Bcr. 17: 61. PMID 25925750 DOI: 10.1186/S13058-015-0567-2 |
0.468 |
|
| 2015 |
Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, Mazoyer S, Chenevix-Trench G, Easton DF, Antoniou AC, Nathanson KL, Laitman Y, Kushnir A, Paluch-Shimon S, ... ... Olopade OI, et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. Jama. 313: 1347-61. PMID 25849179 DOI: 10.1001/Jama.2014.5985 |
0.525 |
|
| 2015 |
Sighoko D, Ogundiran T, Ademola A, Adebamowo C, Chen L, Odedina S, Anetor I, Ndom P, Gakwaya A, Ojengbede O, Huo D, Olopade OI. Breast cancer risk after full-term pregnancies among African women from Nigeria, Cameroon, and Uganda. Cancer. PMID 25781581 DOI: 10.1002/Cncr.29305 |
0.388 |
|
| 2015 |
DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, ... ... Olopade OI, et al. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2911-5. PMID 25712686 DOI: 10.1158/1078-0432.Ccr-14-1760 |
0.462 |
|
| 2015 |
Xu J, Chen Y, Huo D, Khramtsov A, Khramtsova G, Zhang C, Goss KH, Olopade OI. β-catenin regulates c-Myc and CDKN1A expression in breast cancer cells. Molecular Carcinogenesis. PMID 25663530 DOI: 10.1002/Mc.22292 |
0.471 |
|
| 2015 |
Xu J, Prosperi JR, Choudhury N, Olopade OI, Goss KH. β-Catenin is required for the tumorigenic behavior of triple-negative breast cancer cells. Plos One. 10: e0117097. PMID 25658419 DOI: 10.1371/Journal.Pone.0117097 |
0.398 |
|
| 2015 |
Daly B, Olopade OI. Race, ethnicity, and the diagnosis of breast cancer. Jama. 313: 141-2. PMID 25585323 DOI: 10.1001/Jama.2014.17323 |
0.541 |
|
| 2015 |
Kuchenbaecker KB, Ramus SJ, Tyrer J, Lee A, Shen HC, Beesley J, Lawrenson K, McGuffog L, Healey S, Lee JM, Spindler TJ, Lin YG, Pejovic T, Bean Y, Li Q, ... ... Olopade OI, et al. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics. 47: 164-71. PMID 25581431 DOI: 10.1038/ng.3185 |
0.347 |
|
| 2015 |
Baretta Z, Olopade OI, Huo D. Heterogeneity in hormone-receptor status and survival outcomes among women with synchronous and metachronous bilateral breast cancers. Breast (Edinburgh, Scotland). 24: 131-6. PMID 25534718 DOI: 10.1016/J.Breast.2014.12.001 |
0.39 |
|
| 2015 |
Burness ML, Obeid EI, Olopade OI. Triple negative breast cancer in BRCA1 mutation carriers with a complete radiologic response to neoadjuvant paclitaxel: a case report. Clinical Breast Cancer. 15: e155-8. PMID 25445425 DOI: 10.1016/J.Clbc.2014.08.006 |
0.536 |
|
| 2015 |
Pruitt L, Mumuni T, Raikhel E, Ademola A, Ogundiran T, Adenipekun A, Morhason-Bello I, Ojengbede OA, Olopade OI. Social barriers to diagnosis and treatment of breast cancer in patients presenting at a teaching hospital in Ibadan, Nigeria. Global Public Health. 10: 331-44. PMID 25443995 DOI: 10.1080/17441692.2014.974649 |
0.377 |
|
| 2015 |
Churpek JE, Walsh T, Zheng Y, Moton Z, Thornton AM, Lee MK, Casadei S, Watts A, Neistadt B, Churpek MM, Huo D, Zvosec C, Liu F, Niu Q, Marquez R, ... ... Olopade OI, et al. Inherited predisposition to breast cancer among African American women. Breast Cancer Research and Treatment. 149: 31-9. PMID 25428789 DOI: 10.1007/S10549-014-3195-0 |
0.585 |
|
| 2015 |
Sehdev A, Shih YC, Vekhter B, Bissonnette MB, Olopade OI, Polite BN. Metformin for primary colorectal cancer prevention in patients with diabetes: a case-control study in a US population. Cancer. 121: 1071-8. PMID 25424411 DOI: 10.1002/Cncr.29165 |
0.336 |
|
| 2015 |
Peterlongo P, Chang-Claude J, Moysich KB, Rudolph A, Schmutzler RK, Simard J, Soucy P, Eeles RA, Easton DF, Hamann U, Wilkening S, Chen B, Rookus MA, Schmidt MK, van der Baan FH, ... ... Olopade OI, et al. Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 24: 308-16. PMID 25336561 DOI: 10.1158/1055-9965.Epi-14-0532 |
0.523 |
|
| 2015 |
Bradbury AR, Patrick-Miller L, Long J, Powers J, Stopfer J, Forman A, Rybak C, Mattie K, Brandt A, Chambers R, Chung WK, Churpek J, Daly MB, Digiovanni L, Farengo-Clark D, ... ... Olopade O, et al. Development of a tiered and binned genetic counseling model for informed consent in the era of multiplex testing for cancer susceptibility. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 17: 485-92. PMID 25297947 DOI: 10.1038/Gim.2014.134 |
0.372 |
|
| 2015 |
Catenacci DV, Amico AL, Nielsen SM, Geynisman DM, Rambo B, Carey GB, Gulden C, Fackenthal J, Marsh RD, Kindler HL, Olopade OI. Tumor genome analysis includes germline genome: are we ready for surprises? International Journal of Cancer. Journal International Du Cancer. 136: 1559-67. PMID 25123297 DOI: 10.1002/Ijc.29128 |
0.413 |
|
| 2015 |
Grushko TA, Filiaci VL, Montag AG, Apushkin MA, Marzullo B, Monovich L, Ramirez NC, Birrer MJ, Olopade OI, Fleming GF. The value of TOP2A as a target for anthracycline-based chemotherapy in advanced endometrial carcinoma (EC): NRG Oncology/Gynecology Oncology Group study. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E16509 |
0.366 |
|
| 2015 |
O'Donnell PH, Trubetskoy V, Nurhussein-Patterson A, Hall JP, Huo D, Fleming GF, Ingle JN, Mayer IA, Morrow PKH, Storniolo AM, Forero-Torres A, Poznak CHV, Merkel DE, Rosner GL, Olopade OI, et al. Clinical evaluation of germline polymorphisms (SNPs) associated with capecitabine (C) toxicity (tox) in metastatic breast cancer (MBC). Journal of Clinical Oncology. 33: 1049-1049. DOI: 10.1200/Jco.2015.33.15_Suppl.1049 |
0.325 |
|
| 2015 |
Wolf DM, Yau C, Sanil A, Chien J, Wallace A, DeMichele A, Kaplan H, Yee D, Isaacs C, Albain K, Viscuzi R, Boughey J, Moulder S, Chui S, Khan Q, ... ... Olopade OI, et al. Abstract P3-06-25: MammaPrint High1/High2 risk class as a biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P3-06-25 |
0.414 |
|
| 2015 |
Wolf DM, Yau C, Sanil A, Daemen A, Heiser L, Gray J, Brown-Swigart L, Flynn S, Hirst G, Investigators IT, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, ... ... Olopade O, et al. Abstract P3-06-05: Evaluation of anin vitroderived signature of olaparib response (PARPi-7) as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 TRIAL: Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P3-06-05 |
0.43 |
|
| 2015 |
Han YJ, Zhang J, Prat A, Yoshimatsu T, Gomez-Vega M, Kwon J, Perou CM, Kannanganattu P, Olopade OI. Abstract LB-149: A novel strategy to inhibit CpG island hypermethylation and restore BRCA1 expression Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-149 |
0.414 |
|
| 2015 |
Khramtsova GF, Nanda R, Khramtsova EA, Sveen L, Olugbile S, Olopade OI. Abstract 462: Cytotoxic CD8+ T cells and immunosuppressive T regulatory cells are associated with aggressive breast cancer subtypes Cancer Research. 75: 462-462. DOI: 10.1158/1538-7445.Am2015-462 |
0.474 |
|
| 2015 |
Huo D, Clayton WM, Yoshimatsu TF, Chen J, Olopade OI. Abstract 3995: Breast cancer molecular subtypes are reflected in circulating microRNA profiles Cancer Research. 75: 3995-3995. DOI: 10.1158/1538-7445.Am2015-3995 |
0.468 |
|
| 2014 |
Kuchenbaecker KB, Neuhausen SL, Robson M, Barrowdale D, McGuffog L, Mulligan AM, Andrulis IL, Spurdle AB, Schmidt MK, Schmutzler RK, Engel C, Wappenschmidt B, Nevanlinna H, Thomassen M, Southey M, ... ... Olopade OI, et al. Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research : Bcr. 16: 3416. PMID 25919761 DOI: 10.1186/S13058-014-0492-9 |
0.468 |
|
| 2014 |
Lee RT, Barbo A, Lopez G, Melhem-Bertrandt A, Lin H, Olopade OI, Curlin FA. National survey of US oncologists' knowledge, attitudes, and practice patterns regarding herb and supplement use by patients with cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 4095-101. PMID 25403205 DOI: 10.1200/Jco.2014.55.8676 |
0.357 |
|
| 2014 |
Bockhorn J, Prat A, Chang YF, Liu X, Huang S, Shang M, Nwachukwu C, Gomez-Vega MJ, Harrell JC, Olopade OI, Perou CM, Liu H. Differentiation and loss of malignant character of spontaneous pulmonary metastases in patient-derived breast cancer models. Cancer Research. 74: 7406-17. PMID 25339353 DOI: 10.1158/0008-5472.Can-14-1188 |
0.431 |
|
| 2014 |
Chai X, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, Tung N, Weitzel JN, Couch FJ, Hulick PJ, Ganz PA, ... ... Olopade OI, et al. Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment. 148: 397-406. PMID 25311111 DOI: 10.1007/S10549-014-3134-0 |
0.491 |
|
| 2014 |
Qian F, Ogundiran T, Hou N, Ndom P, Gakwaya A, Jombwe J, Morhason-Bello I, Adebamowo C, Ademola A, Ojengbede O, Olopade OI, Huo D. Alcohol consumption and breast cancer risk among women in three sub-Saharan African countries. Plos One. 9: e106908. PMID 25198723 DOI: 10.1371/Journal.Pone.0106908 |
0.459 |
|
| 2014 |
Gierach GL, Li H, Loud JT, Greene MH, Chow CK, Lan L, Prindiville SA, Eng-Wong J, Soballe PW, Giambartolomei C, Mai PL, Galbo CE, Nichols K, Calzone KA, Olopade OI, et al. Relationships between computer-extracted mammographic texture pattern features and BRCA1/2 mutation status: a cross-sectional study. Breast Cancer Research : Bcr. 16: 424. PMID 25159706 DOI: 10.1186/S13058-014-0424-8 |
0.451 |
|
| 2014 |
Gronwald J, Robidoux A, Kim-Sing C, Tung N, Lynch HT, Foulkes WD, Manoukian S, Ainsworth P, Neuhausen SL, Demsky R, Eisen A, Singer CF, Saal H, Senter L, Eng C, ... ... Olopade O, et al. Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment. 146: 421-7. PMID 24951267 DOI: 10.1007/S10549-014-3026-3 |
0.521 |
|
| 2014 |
Feng Y, Stram DO, Rhie SK, Millikan RC, Ambrosone CB, John EM, Bernstein L, Zheng W, Olshan AF, Hu JJ, Ziegler RG, Nyante S, Bandera EV, Ingles SA, Press MF, ... ... Olopade OI, et al. A comprehensive examination of breast cancer risk loci in African American women. Human Molecular Genetics. 23: 5518-26. PMID 24852375 DOI: 10.1093/Hmg/Ddu252 |
0.549 |
|
| 2014 |
Olopade OI. Obituary: Janet Davison Rowley 1925-2013. Cell. 156: 390-1. PMID 24757717 DOI: 10.1016/J.Cell.2014.01.015 |
0.351 |
|
| 2014 |
Osorio A, Milne RL, Kuchenbaecker K, Vaclová T, Pita G, Alonso R, Peterlongo P, Blanco I, de la Hoya M, Duran M, DÃez O, Ramón Y Cajal T, Konstantopoulou I, MartÃnez-Bouzas C, Andrés Conejero R, ... ... Olopade OI, et al. DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. Plos Genetics. 10: e1004256. PMID 24698998 DOI: 10.1371/Journal.Pgen.1004256 |
0.499 |
|
| 2014 |
Adewole I, Martin DN, Williams MJ, Adebamowo C, Bhatia K, Berling C, Casper C, Elshamy K, Elzawawy A, Lawlor RT, Legood R, Mbulaiteye SM, Odedina FT, Olopade OI, Olopade CO, et al. Building capacity for sustainable research programmes for cancer in Africa. Nature Reviews. Clinical Oncology. 11: 251-9. PMID 24614139 DOI: 10.1038/Nrclinonc.2014.37 |
0.378 |
|
| 2014 |
Li H, Giger ML, Sun C, Ponsukcharoen U, Huo D, Lan L, Olopade OI, Jamieson AR, Brown JB, Di Rienzo A. Pilot study demonstrating potential association between breast cancer image-based risk phenotypes and genomic biomarkers. Medical Physics. 41: 031917. PMID 24593735 DOI: 10.1118/1.4865811 |
0.419 |
|
| 2014 |
Harrell JC, Pfefferle AD, Zalles N, Prat A, Fan C, Khramtsov A, Olopade OI, Troester MA, Dudley AC, Perou CM. Endothelial-like properties of claudin-low breast cancer cells promote tumor vascular permeability and metastasis. Clinical & Experimental Metastasis. 31: 33-45. PMID 23975155 DOI: 10.1007/S10585-013-9607-4 |
0.417 |
|
| 2014 |
Ezewuiro OC, Habis MI, Kocherginsky M, Hunn J, Olopade OI, Grushko TA, Romero IL, Fleming GF. A retrospective analysis of the relationship between diabetes, metformin use, and survival in advanced endometrial cancer patients treated with chemotherapy. Journal of Clinical Oncology. 32: 5607-5607. DOI: 10.1200/Jco.2014.32.15_Suppl.5607 |
0.347 |
|
| 2014 |
Metcalfe KA, Lynch HT, Snyder CL, Foulkes W, Tung NM, Kim-Sing C, Olopade OI, Eisen A, Rosen B, Sun P, Narod S. The impact of oophorectomy on survival after breast cancer in BRCA1 and BRCA2 mutation carriers. Journal of Clinical Oncology. 32: 1507-1507. DOI: 10.1200/Jco.2014.32.15_Suppl.1507 |
0.552 |
|
| 2014 |
Padela AI, Murrar S, Adviento B, Hosseinain Z, Peek M, Olopade O, Curline F. Abstract C52: Associations between religion-related factors and breast cancer screening among American Muslims Cancer Epidemiology, Biomarkers & Prevention. 23. DOI: 10.1158/1538-7755.Disp13-C52 |
0.476 |
|
| 2014 |
Amico A, Nielsen S, Geynisman D, Rambo B, Carey GB, Gulden C, Fackenthal J, Olopade O, Catenacci D. Abstract 07: Challenges of applying tumor genome analysis to the germline: Examples from GI oncology Cancer Research. 74: 7-7. DOI: 10.1158/1538-7445.Cansusc14-07 |
0.452 |
|
| 2014 |
Feng Y, Chen GK, Stram DO, Millikan RC, Ambrosone CB, John EM, Bernstein L, Zheng W, Olshan AF, Hu JJ, Ziegler RG, Nyante S, Bandera EV, Ingles SA, Press MF, ... ... Olopade OI, et al. Abstract 943: A comprehensive examination of breast cancer risk loci in African American women Cancer Research. 74: 943-943. DOI: 10.1158/1538-7445.Am2014-943 |
0.551 |
|
| 2014 |
Poli EC, Tolbert R, Zhang J, Han Y, Olopade OI. Abstract 3559A: Molecular subtype-specific methylation of the miR-29c promoter in breast cancer correlates with basal-like pattern of gene expression Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-3559A |
0.396 |
|
| 2014 |
Han YJ, Olopade OI. Abstract 3306: Aberrant expression of ribosomal protein p1 and its pseudogene in breast tumors Cancer Research. 74: 3306-3306. DOI: 10.1158/1538-7445.Am2014-3306 |
0.472 |
|
| 2014 |
Khramtsova GF, Khramtsov AI, Sveen L, Odetunde A, Adeyanju OO, Olopade OI, Olayiwola OA. Abstract 3278: The effect of cold ischemia time on protein expression in breast cancer tissues Cancer Research. 74: 3278-3278. DOI: 10.1158/1538-7445.Am2014-3278 |
0.444 |
|
| 2014 |
Hardeman A, Grushko TA, Gomez MJ, Coyle M, Nakamura Y, Olopade OI. Abstract 2386: Molecular-cytogenetic analysis of the maternal embryonic leucine-zipper kinase (MELK) oncogene in cancer Cancer Research. 74: 2386-2386. DOI: 10.1158/1538-7445.Am2014-2386 |
0.483 |
|
| 2014 |
Glas A, Peeters J, Yau C, Wolf D, Sanil A, Li Y, Severson T, Linn S, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, ... ... Olopade O, et al. 532 Evaluation of a BRCAness signature as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY 2 trial European Journal of Cancer. 50: 173. DOI: 10.1016/S0959-8049(14)70658-6 |
0.406 |
|
| 2014 |
Grushko TA, Filiaci VL, Montag AG, Apushkin M, Gomez MJ, Marzullo B, Monovich L, Ramirez N, Birrer MJ, Olopade OI, Fleming G. Evaluation of slide storage and detection of molecular markers by immunohistochemistry (IHC) in formalin-fixed, paraffin embedded endometrial cancer tissues from a clinical trial: A GOG study Gynecologic Oncology. 133: 174-175. DOI: 10.1016/J.Ygyno.2014.03.460 |
0.348 |
|
| 2013 |
Walsh T, Zheng Y, Casadei S, Thornton AM, Lee MK, Churpek M, Huo D, Zvosec C, Liu F, Niu Q, Zhang J, Fackenthal J, King MC, Olopade OI. Inherited mutations in breast cancer genes in African American breast cancer patients revealed by targeted genomic capture and next-generation sequencing. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: CRA1501. PMID 28136065 DOI: 10.1200/Jco.2013.31.15_Suppl.Cra1501 |
0.551 |
|
| 2013 |
Yamaguchi K, Schacht D, Newstead GM, Bradbury AR, Verp MS, Olopade OI, Abe H. Breast cancer detected on an incident (second or subsequent) round of screening MRI: MRI features of false-negative cases. Ajr. American Journal of Roentgenology. 201: 1155-63. PMID 24147491 DOI: 10.2214/Ajr.12.9707 |
0.472 |
|
| 2013 |
Valentini A, Lubinski J, Byrski T, Ghadirian P, Moller P, Lynch HT, Ainsworth P, Neuhausen SL, Weitzel J, Singer CF, Olopade OI, Saal H, Lyonnet DS, Foulkes WD, Kim-Sing C, et al. The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation. Breast Cancer Research and Treatment. 142: 177-85. PMID 24136669 DOI: 10.1007/S10549-013-2729-1 |
0.532 |
|
| 2013 |
Oluwasola AO, Malaka D, Khramtsov AI, Ikpatt OF, Odetunde A, Adeyanju OO, Sveen WE, Falusi AG, Huo D, Olopade OI. Use of Web-based training for quality improvement between a field immunohistochemistry laboratory in Nigeria and its United States-based partner institution. Annals of Diagnostic Pathology. 17: 526-30. PMID 24095629 DOI: 10.1016/J.Anndiagpath.2013.07.003 |
0.41 |
|
| 2013 |
Hou N, Hong S, Wang W, Olopade OI, Dignam JJ, Huo D. Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density. Journal of the National Cancer Institute. 105: 1365-72. PMID 24003037 DOI: 10.1093/Jnci/Djt207 |
0.543 |
|
| 2013 |
Bhatta SS, Hou N, Moton ZN, Polite BN, Fleming GF, Olopade OI, Huo D, Hong S. Factors associated with compliance to adjuvant hormone therapy in Black and White women with breast cancer. Springerplus. 2: 356. PMID 23961419 DOI: 10.1186/2193-1801-2-356 |
0.5 |
|
| 2013 |
Jene-Sanz A, Váraljai R, Vilkova AV, Khramtsova GF, Khramtsov AI, Olopade OI, Lopez-Bigas N, Benevolenskaya EV. Expression of polycomb targets predicts breast cancer prognosis. Molecular and Cellular Biology. 33: 3951-61. PMID 23918806 DOI: 10.1128/Mcb.00426-13 |
0.492 |
|
| 2013 |
Hou N, Ogundiran T, Ojengbede O, Morhason-Bello I, Zheng Y, Fackenthal J, Adebamowo C, Anetor I, Akinleye S, Olopade OI, Huo D. Risk factors for pregnancy-associated breast cancer: a report from the Nigerian Breast Cancer Study. Annals of Epidemiology. 23: 551-7. PMID 23880155 DOI: 10.1016/J.Annepidem.2013.06.008 |
0.499 |
|
| 2013 |
Arowolo OA, Njiaju UO, Ogundiran TO, Abidoye O, Lawal OO, Obajimi M, Adetiloye AV, Im HK, Akinkuolie AA, Oluwasola A, Adelusola K, Kayode AA, Agbakwuru AE, Oduntan H, Babalola CP, ... ... Olopade OC, ... ... Olopade OI, et al. Neo-adjuvant capecitabine chemotherapy in women with newly diagnosed locally advanced breast cancer in a resource-poor setting (Nigeria): efficacy and safety in a phase II feasibility study. The Breast Journal. 19: 470-7. PMID 23865786 DOI: 10.1200/Jco.2012.30.15_Suppl.E11554 |
0.401 |
|
| 2013 |
Ren J, Jin F, Yu Z, Zhao L, Wang L, Bai X, Zhao H, Yao W, Mi X, Wang E, Olopade OI, Wei M. MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency. Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine. 34: 3945-58. PMID 23860775 DOI: 10.1007/S13277-013-0983-9 |
0.541 |
|
| 2013 |
Shy BR, Wu CI, Khramtsova GF, Zhang JY, Olopade OI, Goss KH, Merrill BJ. Regulation of Tcf7l1 DNA binding and protein stability as principal mechanisms of Wnt/β-catenin signaling. Cell Reports. 4: 1-9. PMID 23810553 DOI: 10.1016/J.Celrep.2013.06.001 |
0.323 |
|
| 2013 |
Wang PY, Huo D, Sun C, Olopade OI. The use of allelic imbalance to ascertain cis-regulation for human UGT2B7 in vivo. European Journal of Clinical Pharmacology. 69: 1733-5. PMID 23740002 DOI: 10.1007/S00228-013-1538-0 |
0.346 |
|
| 2013 |
Obeid E, Nanda R, Fu YX, Olopade OI. The role of tumor-associated macrophages in breast cancer progression (review). International Journal of Oncology. 43: 5-12. PMID 23673510 DOI: 10.3892/Ijo.2013.1938 |
0.357 |
|
| 2013 |
Davis MB, Liu X, Wang S, Reeves J, Khramtsov A, Huo D, Olopade OI. Expression and sub-cellular localization of an epigenetic regulator, co-activator arginine methyltransferase 1 (CARM1), is associated with specific breast cancer subtypes and ethnicity. Molecular Cancer. 12: 40. PMID 23663560 DOI: 10.1186/1476-4598-12-40 |
0.466 |
|
| 2013 |
Ma CX, Suman VJ, Goetz M, Haluska P, Moynihan T, Nanda R, Olopade O, Pluard T, Guo Z, Chen HX, Erlichman C, Ellis MJ, Fleming GF. A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer. Breast Cancer Research and Treatment. 139: 145-53. PMID 23605083 DOI: 10.1007/S10549-013-2528-8 |
0.431 |
|
| 2013 |
Kingham TP, Alatise OI, Vanderpuye V, Casper C, Abantanga FA, Kamara TB, Olopade OI, Habeebu M, Abdulkareem FB, Denny L. Treatment of cancer in sub-Saharan Africa. The Lancet. Oncology. 14: e158-67. PMID 23561747 DOI: 10.1016/S1470-2045(12)70472-2 |
0.337 |
|
| 2013 |
Couch FJ, Wang X, McGuffog L, Lee A, Olswold C, Kuchenbaecker KB, Soucy P, Fredericksen Z, Barrowdale D, Dennis J, Gaudet MM, Dicks E, Kosel M, Healey S, Sinilnikova OM, ... ... Olopade OI, et al. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. Plos Genetics. 9: e1003212. PMID 23544013 DOI: 10.1371/Journal.Pgen.1003212 |
0.526 |
|
| 2013 |
Zheng Y, Ogundiran TO, Falusi AG, Nathanson KL, John EM, Hennis AJ, Ambs S, Domchek SM, Rebbeck TR, Simon MS, Nemesure B, Wu SY, Leske MC, Odetunde A, Niu Q, ... ... Olopade OI, et al. Fine mapping of breast cancer genome-wide association studies loci in women of African ancestry identifies novel susceptibility markers. Carcinogenesis. 34: 1520-8. PMID 23475944 DOI: 10.1093/Carcin/Bgt090 |
0.532 |
|
| 2013 |
Khoury MJ, Lam TK, Ioannidis JP, Hartge P, Spitz MR, Buring JE, Chanock SJ, Croyle RT, Goddard KA, Ginsburg GS, Herceg Z, Hiatt RA, Hoover RN, Hunter DJ, Kramer BS, ... ... Olopade OI, et al. Transforming epidemiology for 21st century medicine and public health. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 22: 508-16. PMID 23462917 DOI: 10.1158/1055-9965.Epi-13-0146 |
0.305 |
|
| 2013 |
Di LJ, Byun JS, Wong MM, Wakano C, Taylor T, Bilke S, Baek S, Hunter K, Yang H, Lee M, Zvosec C, Khramtsova G, Cheng F, Perou CM, Miller CR, ... ... Olopade OI, et al. Genome-wide profiles of CtBP link metabolism with genome stability and epithelial reprogramming in breast cancer. Nature Communications. 4: 1449. PMID 23385593 DOI: 10.1038/Ncomms2438 |
0.496 |
|
| 2013 |
Narod SA, Metcalfe K, Lynch HT, Ghadirian P, Robidoux A, Tung N, Gaughan E, Kim-Sing C, Olopade OI, Foulkes WD, Robson M, Offit K, Jakubowska A, Byrski T, Huzarski T, et al. Should all BRCA1 mutation carriers with stage i breast cancer receive chemotherapy? Breast Cancer Research and Treatment. 138: 273-279. PMID 23381743 DOI: 10.1007/S10549-013-2429-X |
0.517 |
|
| 2013 |
Bockhorn J, Dalton R, Nwachukwu C, Huang S, Prat A, Yee K, Chang YF, Huo D, Wen Y, Swanson KE, Qiu T, Lu J, Young Park S, Eileen Dolan M, Perou CM, ... Olopade OI, et al. MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11 Nature Communications. 4. PMID 23340433 DOI: 10.1038/Ncomms2393 |
0.446 |
|
| 2013 |
Baretta Z, Guindalini RS, Khramtsova G, Olopade OI. Resistance to trastuzumab in HER2-positive mucinous invasive ductal breast carcinoma. Clinical Breast Cancer. 13: 156-8. PMID 23276464 DOI: 10.1016/J.Clbc.2012.11.007 |
0.404 |
|
| 2013 |
Bockhorn J, Yee K, Chang YF, Prat A, Huo D, Nwachukwu C, Dalton R, Huang S, Swanson KE, Perou CM, Olopade OI, Clarke MF, Greene GL, Liu H. MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion Breast Cancer Research and Treatment. 137: 373-382. PMID 23224145 DOI: 10.1007/S10549-012-2346-4 |
0.486 |
|
| 2013 |
Wood AM, Medved M, Bacchus ID, Al-Hallaq HA, Shimauchi A, Newstead GM, Olopade OI, Venkataraman SS, Ivancevic MK, Karczmar GS. Classification of breast lesions pre-contrast injection using water resonance lineshape analysis. Nmr in Biomedicine. 26: 569-77. PMID 23165988 DOI: 10.1002/Nbm.2893 |
0.326 |
|
| 2013 |
Chen F, Chen GK, Stram DO, Millikan RC, Ambrosone CB, John EM, Bernstein L, Zheng W, Palmer JR, Hu JJ, Rebbeck TR, Ziegler RG, Nyante S, Bandera EV, Ingles SA, ... ... Olopade OI, et al. A genome-wide association study of breast cancer in women of African ancestry. Human Genetics. 132: 39-48. PMID 22923054 DOI: 10.1007/S00439-012-1214-Y |
0.489 |
|
| 2013 |
Churpek JE, Walsh T, Zheng Y, Casadei S, Thornton AM, Lee MK, Churpek M, Huo D, Zvosec C, Liu F, Niu Q, Zhang J, Fackenthal J, King M, Olopade OI. Inherited mutations in breast cancer genes in African American breast cancer patients revealed by targeted genomic capture and next-generation sequencing. Journal of Clinical Oncology. 31: CRA1501-CRA1501. DOI: 10.1200/jco.2013.31.18_suppl.cra1501 |
0.471 |
|
| 2013 |
Kupfer S, Guindalini RSC, Gulden C, Ukaegbu CI, Koeppe E, Conrad P, Hampel H, Stoffel EM, Syngal S, Olopade OI. Cancer risks and mutation spectrum of mismatch repair genes in African American families with Lynch syndrome. Journal of Clinical Oncology. 31: 1530-1530. DOI: 10.1200/Jco.2013.31.15_Suppl.1530 |
0.451 |
|
| 2013 |
Guindalini RSC, Huang Y, Obeid E, Patrick-Miller L, Bradbury AR, Verp MS, Hong S, Wroblewski K, Abe H, Karczmar GS, Newstead G, Olopade OI. Breast cancer surveillance in high-risk women with magnetic resonance imaging every 6 months. Journal of Clinical Oncology. 31: 1506-1506. DOI: 10.1200/Jco.2013.31.15_Suppl.1506 |
0.472 |
|
| 2013 |
Abe H, Guindalini RSC, Obeid E, Patrick-Miller LJ, Bradbury AR, Verp MS, Hong S, Wroblewski K, Karczmar GS, Newstead G, Olopade OI. Recall rate in a semi-annual breast surveillance program for high-risk women. Journal of Clinical Oncology. 31: 11084-11084. DOI: 10.1200/Jco.2013.31.15_Suppl.11084 |
0.491 |
|
| 2013 |
Obeid E, Nanda R, Li T, Zhang B, Mueller J, Olopade OI. Association of downregulation of toll-like receptor 3 (TLR3) expression with aggressive breast cancer (BC). Journal of Clinical Oncology. 31: 11035-11035. DOI: 10.1200/Jco.2013.31.15_Suppl.11035 |
0.446 |
|
| 2013 |
Grushko TA, Gomez-Vega MJ, Prat A, Mueller J, Coyle M, Perou CM, Guindalini RSC, Obeid E, Irie H, Olopade OI. Protein tyrosine kinase 6 (PTK6, BRK) amplification in HER2+ breast cancer as a mechanism of HER2 resistance. Journal of Clinical Oncology. 31: 11021-11021. DOI: 10.1200/Jco.2013.31.15_Suppl.11021 |
0.535 |
|
| 2013 |
Harrell JC, Pfefferle A, Zalles N, Prat A, Fan C, Khramtsov A, Olopade O, Troester M, Dudley A, Perou C. Abstract A027: Endothelial-like properties of triple-negative claudin-low breast cancer cells promote tumor-vascular interactions and tumor permeability Molecular Cancer Research. 11. DOI: 10.1158/1557-3125.Advbc-A027 |
0.44 |
|
| 2013 |
Liu H, Bockhorn J, Dalton R, Nwachukwu C, Huang S, Prat A, Yee K, Chang Y, Huo D, Lu J, Dolan E, Perou CM, Olopade OI, Clarke MF, Greene G. Abstract 832: MicroRNA-30c inhibits human breast tumor chemo-resistance by regulating twinfinlin-1 (TWF1) and IL-11. Cancer Research. 73: 832-832. DOI: 10.1158/1538-7445.Am2013-832 |
0.424 |
|
| 2013 |
Yoshimatsu TF, Yao K, Kaul K, Turk MA, Olopade OI, Huo D. Abstract 5332: MicroRNA profile of triple-negative breast cancer and prognosis. Cancer Research. 73: 5332-5332. DOI: 10.1158/1538-7445.Am2013-5332 |
0.398 |
|
| 2013 |
Poli E, Han Y, Gomez M, Zhang J, Olopade O. Abstract 4199: Regulation of microRNA-29c expression in different subtypes of breast cancer. Cancer Research. 73: 4199-4199. DOI: 10.1158/1538-7445.Am2013-4199 |
0.417 |
|
| 2013 |
Xu J, Chen Y, Khramtsov A, Huo D, Goss K, Olopade OI. Abstract 3132: Beta-catenin regulates c-Myc and CDKN1A expression in breast cancer cells. Cancer Research. 73: 3132-3132. DOI: 10.1158/1538-7445.Am2013-3132 |
0.434 |
|
| 2013 |
Han Y, Zhang J, Zheng Y, Huo D, Olopade OI. Abstract 2565: Functional characterization of genetic variants at 16q12 associated with breast cancer in women of African ancestry. Cancer Research. 73: 2565-2565. DOI: 10.1158/1538-7445.Am2013-2565 |
0.54 |
|
| 2013 |
Padela AI, Murrar S, Adviento B, Curlin F, Olopade O. Abstract 1363: Associations between fatalistic beliefs, modesty concerns and breast cancer screening in the American Muslim community. Cancer Research. 73: 1363-1363. DOI: 10.1158/1538-7445.Am2013-1363 |
0.474 |
|
| 2012 |
Njiaju UO, Olopade OI. Genetic determinants of breast cancer risk: a review of current literature and issues pertaining to clinical application. The Breast Journal. 18: 436-42. PMID 22957996 DOI: 10.1111/J.1524-4741.2012.01274.X |
0.553 |
|
| 2012 |
Zheng Y, Huo D, Zhang J, Yoshimatsu TF, Niu Q, Olopade OI. Microsatellites in the estrogen receptor (ESR1, ESR2) and androgen receptor (AR) genes and breast cancer risk in African American and Nigerian women. Plos One. 7: e40494. PMID 22792352 DOI: 10.1371/Journal.Pone.0040494 |
0.517 |
|
| 2012 |
Zhang J, Fackenthal JD, Zheng Y, Huo D, Hou N, Niu Q, Zvosec C, Ogundiran TO, Hennis AJ, Leske MC, Nemesure B, Wu SY, Olopade OI. Recurrent BRCA1 and BRCA2 mutations in breast cancer patients of African ancestry. Breast Cancer Research and Treatment. 134: 889-94. PMID 22739995 DOI: 10.1007/S10549-012-2136-Z |
0.548 |
|
| 2012 |
Ding YC, McGuffog L, Healey S, Friedman E, Laitman Y, Paluch-Shimon S, Kaufman B, Liljegren A, Lindblom A, Olsson H, Kristoffersson U, Stenmark-Askmalm M, Melin B, Domchek SM, ... ... Olopade OI, et al. A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 21: 1362-70. PMID 22729394 DOI: 10.1158/1055-9965.Epi-12-0229 |
0.53 |
|
| 2012 |
Pritchard CC, Smith C, Salipante SJ, Lee MK, Thornton AM, Nord AS, Gulden C, Kupfer SS, Swisher EM, Bennett RL, Novetsky AP, Jarvik GP, Olopade OI, Goodfellow PJ, King MC, et al. ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing. The Journal of Molecular Diagnostics : Jmd. 14: 357-66. PMID 22658618 DOI: 10.1016/J.Jmoldx.2012.03.002 |
0.389 |
|
| 2012 |
Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, ... ... Olopade OI, et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 3242-9. PMID 22649152 DOI: 10.1200/Jco.2011.39.2779 |
0.443 |
|
| 2012 |
Finkelman BS, Rubinstein WS, Friedman S, Friebel TM, Dubitsky S, Schonberger NS, Shoretz R, Singer CF, Blum JL, Tung N, Olopade OI, Weitzel JN, Lynch HT, Snyder C, Garber JE, et al. Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 1321-8. PMID 22430266 DOI: 10.1200/Jco.2011.37.8133 |
0.537 |
|
| 2012 |
Ogundiran TO, Huo D, Adenipekun A, Campbell O, Oyesegun R, Akang E, Adebamowo C, Olopade OI. Body fat distribution and breast cancer risk: Findings from the Nigerian breast cancer study Cancer Causes and Control. 23: 565-574. PMID 22367701 DOI: 10.1007/S10552-012-9916-Y |
0.518 |
|
| 2012 |
Huo D, Zheng Y, Ogundiran TO, Adebamowo C, Nathanson KL, Domchek SM, Rebbeck TR, Simon MS, John EM, Hennis A, Nemesure B, Wu SY, Leske MC, Ambs S, Niu Q, ... ... Olopade OI, et al. Evaluation of 19 susceptibility loci of breast cancer in women of African ancestry. Carcinogenesis. 33: 835-40. PMID 22357627 DOI: 10.1093/Carcin/Bgs093 |
0.455 |
|
| 2012 |
Li H, Giger ML, Lan L, Bancroft Brown J, MacMahon A, Mussman M, Olopade OI, Sennett C. Computerized analysis of mammographic parenchymal patterns on a large clinical dataset of full-field digital mammograms: robustness study with two high-risk datasets. Journal of Digital Imaging. 25: 591-8. PMID 22246204 DOI: 10.1007/S10278-012-9452-Z |
0.494 |
|
| 2012 |
Hou N, Zheng Y, Gamazon ER, Ogundiran TO, Adebamowo C, Nathanson KL, Domchek SM, Rebbeck TR, Simon MS, John EM, Hennis A, Nemesure B, Wu SY, Leske MC, Ambs S, ... ... Olopade OI, et al. Genetic susceptibility to type 2 diabetes and breast cancer risk in women of European and African ancestry. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 21: 552-6. PMID 22237986 DOI: 10.1158/1055-9965.Epi-11-0979 |
0.525 |
|
| 2012 |
Liu D, Wu HZ, Zhang YN, Kang H, Sun MJ, Wang EH, Yang XL, Lian MQ, Yu ZJ, Zhao L, Olopade OI, Wei MJ. DNA repair genes XPC, XPG polymorphisms: relation to the risk of colorectal carcinoma and therapeutic outcome with Oxaliplatin-based adjuvant chemotherapy. Molecular Carcinogenesis. 51: E83-93. PMID 22213216 DOI: 10.1002/Mc.21862 |
0.326 |
|
| 2012 |
Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, ... ... Olopade OI, et al. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Research and Treatment. 132: 1049-62. PMID 22198468 DOI: 10.1007/S10549-011-1895-2 |
0.46 |
|
| 2012 |
Zheng Y, Ogundiran TO, Adebamowo C, Nathanson KL, Domchek SM, Rebbeck TR, Simon MS, John EM, Hennis A, Nemesure B, Wu SY, Leske MC, Ambs S, Niu Q, Zhang J, ... ... Olopade OI, et al. Lack of association between common single nucleotide polymorphisms in the TERT-CLPTM1L locus and breast cancer in women of African ancestry. Breast Cancer Research and Treatment. 132: 341-5. PMID 22134622 DOI: 10.1007/S10549-011-1890-7 |
0.543 |
|
| 2012 |
Sylvester BE, Huo D, Khramtsov A, Zhang J, Smalling RV, Olugbile S, Polite BN, Olopade OI. Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 350-9. PMID 22114137 DOI: 10.1158/1078-0432.Ccr-11-1397 |
0.794 |
|
| 2012 |
Zhao L, Yu Z, Li Y, Wen X, Ma W, Wang L, Ren J, Liu C, He M, Bai X, Sun M, Zheng Z, Mi X, Wang E, Olopade OI, et al. Clinical implications of ERβ methylation on sporadic breast cancers in Chinese women. Medical Oncology (Northwood, London, England). 29: 1569-75. PMID 22105146 DOI: 10.1007/S12032-011-0107-6 |
0.503 |
|
| 2012 |
Weigman VJ, Chao HH, Shabalin AA, He X, Parker JS, Nordgard SH, Grushko T, Huo D, Nwachukwu C, Nobel A, Kristensen VN, Børresen-Dale AL, Olopade OI, Perou CM. Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Research and Treatment. 133: 865-80. PMID 22048815 DOI: 10.1007/S10549-011-1846-Y |
0.451 |
|
| 2012 |
Bai X, Jin F, Fu Y, Yu Z, Zhao L, Ren J, Li Y, Jiao X, Zhao H, Yao W, Mi X, Wang E, Olopade OI, Zhou M, Wei M. Clinicopathological significance and prognostic value of Xeroderma pigmentosum complementary group C (XPC) expression in sporadic breast cancer patients. Medical Oncology (Northwood, London, England). 29: 1543-53. PMID 22038723 DOI: 10.1007/S12032-011-0086-7 |
0.542 |
|
| 2012 |
Fackenthal JD, Zhang J, Zhang B, Zheng Y, Hagos F, Burrill DR, Niu Q, Huo D, Sveen WE, Ogundiran T, Adebamowo C, Odetunde A, Falusi AG, Olopade OI. High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients. International Journal of Cancer. Journal International Du Cancer. 131: 1114-23. PMID 22034289 DOI: 10.1002/Ijc.27326 |
0.569 |
|
| 2012 |
Zheng Y, Zhang J, Niu Q, Huo D, Olopade OI. Novel germline PALB2 truncating mutations in African American breast cancer patients. Cancer. 118: 1362-70. PMID 21932393 DOI: 10.1002/Cncr.26388 |
0.557 |
|
| 2012 |
Ulasov IV, Kaverina NV, Pytel P, Thaci B, Liu F, Hurst DR, Welch DR, Sattar HA, Olopade OI, Baryshnikov AY, Kadagidze ZG, Lesniak MS. Clinical significance of KISS1 protein expression for brain invasion and metastasis. Cancer. 118: 2096-105. PMID 21928364 DOI: 10.1002/Cncr.26525 |
0.468 |
|
| 2012 |
Sun C, Huo D, Nemesure B, Hennis A, Leske MC, Wu SY, Niu Q, Olopade OI, Di Rienzo A. Lack of association between common UGT2B nonsynonymous single-nucleotide polymorphisms and breast cancer in populations of African ancestry. International Journal of Cancer. Journal International Du Cancer. 130: 2740-2. PMID 21780111 DOI: 10.1002/Ijc.26300 |
0.364 |
|
| 2012 |
Melhem-Bertrandt A, Bojadzieva J, Ready KJ, Obeid E, Liu DD, Gutierrez-Barrera AM, Litton JK, Olopade OI, Hortobagyi GN, Strong LC, Arun BK. Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer. 118: 908-13. PMID 21761402 DOI: 10.1002/Cncr.26377 |
0.539 |
|
| 2012 |
Sun C, Southard C, Huo D, Hernandez RD, Witonsky DB, Olopade OI, Di Rienzo A. SNP discovery, expression and cis-regulatory variation in the UGT2B genes. The Pharmacogenomics Journal. 12: 287-96. PMID 21358749 DOI: 10.1038/Tpj.2011.2 |
0.331 |
|
| 2012 |
Fleming GF, Suman V, Goetz MP, Haluska P, Moynihan TJ, Nanda R, Olopade OI, Pluard TJ, Erlichman C, Chen HX, Guo Z, Ellis MJ, Ma CX. A phase I trial of the IGF-1R antibody IMC-A12 in combination with temsirolimus in patients with metastatic breast cancer. Journal of Clinical Oncology. 30: 534-534. DOI: 10.1200/Jco.2012.30.15_Suppl.534 |
0.347 |
|
| 2012 |
Hou N, Gakwaya A, Ndom P, Ojengbede O, Olopade OI, Huo D. Abstract 674: A pilot study of physical activity and breast cancer risk in Africa Cancer Research. 72: 674-674. DOI: 10.1158/1538-7445.Am2012-674 |
0.453 |
|
| 2012 |
Huang S, Yee K, Bockhorn J, Kim S, Huo D, Olopade O, Liu H, Greene G. Abstract 4198: Transcriptional regulation of breast cancer microRNAs by GATA3 and TFAP2A Cancer Research. 72: 4198-4198. DOI: 10.1158/1538-7445.Am2012-4198 |
0.458 |
|
| 2012 |
Liu H, Bockhorn J, Dalton R, Nwachukwu C, Prat A, Yee K, Huang S, Swanson K, Perou CM, Olopade OI, Clarke MF, Greene GL. Abstract 3331: MicroRNAs regulate breast cancer stem cells and spontaneous metastases in orthotopic xenograft models Cancer Research. 72: 3331-3331. DOI: 10.1158/1538-7445.Am2012-3331 |
0.424 |
|
| 2012 |
Yoshimatsu TF, Zheng Y, Zhang J, Huo D, Olopade OI. Abstract 2620: Contribution of risk variant in miR-125b binding site of BMPR1B in women of African ancestry with breast cancer Cancer Research. 72: 2620-2620. DOI: 10.1158/1538-7445.Am2012-2620 |
0.498 |
|
| 2012 |
Zheng Y, Ogundiran TO, Adebamowo C, Nathanson KL, Domchek SM, Rebbeck TR, Simon MS, John EM, Hennis A, Nemesure B, Wu S, Leske MC, Ambs S, Niu Q, Zhang J, ... ... Olopade OI, et al. Abstract 2606: Absence of association between common genetic polymorphisms in the TERT-CLPTM1L locus and breast cancer risk in women of African descent Cancer Research. 72: 2606-2606. DOI: 10.1158/1538-7445.Am2012-2606 |
0.509 |
|
| 2012 |
Han YJ, Prat A, Osborne RA, Perou CM, Olopade OI. Abstract 200: A transcribed BRCA1 pseudogene regulates gene expression and promotes breast cancer cell proliferation. Cancer Research. 72: 200-200. DOI: 10.1158/1538-7445.Am2012-200 |
0.488 |
|
| 2012 |
Khramtsova GF, Islam ABMMK, Khramtsov AI, Lyman P, Chuanhong L, Jene-Sanz A, Sveen WE, Huo D, Lopez-Bigas N, Benevolenskaya EV, Olopade OI. Abstract 1061: EZH2 expression in different subtypes of human breast cancer Cancer Research. 72: 1061-1061. DOI: 10.1158/1538-7445.Am2012-1061 |
0.489 |
|
| 2012 |
Obeid EI, Zhang B, Olopade OI. Abstract B69: Macrophages along with pathogens in the microenvironment enhance the aggressive behavior of triple-negative breast cancer (TNBC) in an in vitro model. Cancer Epidemiology, Biomarkers & Prevention. 21. DOI: 10.1158/1055-9965.Disp12-B69 |
0.438 |
|
| 2012 |
Miller ME, Kunnavakkam R, Khramtsova G, Khramtsov A, Sylvester B, Huo D, Olopade OI, Goss KH. Abstract B53: Analysis of Wnt signaling as a determinant of racial disparities in colorectal cancer outcomes. Cancer Epidemiology, Biomarkers & Prevention. 21. DOI: 10.1158/1055-9965.Disp12-B53 |
0.789 |
|
| 2011 |
Bhatta S, Hou N, Huo D, Polite BN, Fleming GF, Olopade OI, Hong S. Compliance to adjuvant hormone therapy for black and white women with breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 1555. PMID 28024043 DOI: 10.1200/Jco.2011.29.15_Suppl.1555 |
0.518 |
|
| 2011 |
Cappetta A, Nanda R, Liao C, Huo D, Chen LF, Artioli G, Zagonel V, Olopade OI. Adjuvant chemotherapy in American and Italian patients with BRCA1/2-associated breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 1084. PMID 28021264 DOI: 10.1200/Jco.2011.29.15_Suppl.1084 |
0.552 |
|
| 2011 |
Liu H, Bockhorn J, Dalton R, Dolan ME, Perou CM, Olopade OI, Clarke MF, Greene G. Roles of miRNAs in breast cancer stem cells, drug sensitivity, and spontaneous metastases in orthotopic human-in-mouse models. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 1082. PMID 28021259 DOI: 10.1200/Jco.2011.29.15_Suppl.1082 |
0.455 |
|
| 2011 |
Mukhtar R, Moore AP, Tandon V, Nseyo O, Au A, Baehner FL, Adisa CA, Eleweke N, Olopade OI, Moore DH, Campbell M, Esserman L. Identification of pathogenic macrophages in breast cancer as markers of tumor aggressiveness. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 1043. PMID 28020686 DOI: 10.1200/jco.2011.29.15_suppl.1043 |
0.409 |
|
| 2011 |
Mulligan AM, Couch FJ, Barrowdale D, Domchek SM, Eccles D, Nevanlinna H, Ramus SJ, Robson M, Sherman M, Spurdle AB, Wappenschmidt B, Lee A, McGuffog L, Healey S, Sinilnikova OM, ... ... Olopade O, et al. Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research : Bcr. 13: R110. PMID 22053997 DOI: 10.1186/Bcr3052 |
0.555 |
|
| 2011 |
Polite BN, Sylvester BE, Olopade OI. Race and subset analyses in clinical trials: time to get serious about data integration. Journal of the National Cancer Institute. 103: 1486-8. PMID 21997133 DOI: 10.1093/Jnci/Djr382 |
0.775 |
|
| 2011 |
Medved M, Fan X, Abe H, Newstead GM, Wood AM, Shimauchi A, Kulkarni K, Ivancevic MK, Pesce LL, Olopade OI, Karczmar GS. Non-contrast enhanced MRI for evaluation of breast lesions: comparison of non-contrast enhanced high spectral and spatial resolution (HiSS) images versus contrast enhanced fat-suppressed images. Academic Radiology. 18: 1467-74. PMID 21962476 DOI: 10.1016/J.Acra.2011.07.017 |
0.337 |
|
| 2011 |
Rebbeck TR, Mitra N, Domchek SM, Wan F, Friebel TM, Tran TV, Singer CF, Tea MK, Blum JL, Tung N, Olopade OI, Weitzel JN, Lynch HT, Snyder CL, Garber JE, et al. Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes. Cancer Research. 71: 5792-805. PMID 21799032 DOI: 10.1158/0008-5472.Can-11-0773 |
0.532 |
|
| 2011 |
Khan O, Blanco A, Conrad P, Gulden C, Moss TZ, Olopade OI, Kupfer SS, Terdiman J. Performance of Lynch syndrome predictive models in a multi-center US referral population. The American Journal of Gastroenterology. 106: 1822-1827. PMID 21747416 DOI: 10.1038/Ajg.2011.200 |
0.357 |
|
| 2011 |
Neuhausen SL, Brummel S, Ding YC, Steele L, Nathanson KL, Domchek S, Rebbeck TR, Singer CF, Pfeiler G, Lynch HT, Garber JE, Couch F, Weitzel JN, Godwin A, Narod SA, ... ... Olopade OI, et al. Genetic variation in IGF2 and HTRA1 and breast cancer risk among BRCA1 and BRCA2 carriers. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 20: 1690-702. PMID 21708937 DOI: 10.1158/1055-9965.Epi-10-1336 |
0.52 |
|
| 2011 |
Chen Y, Xu J, Borowicz S, Collins C, Huo D, Olopade OI. c-Myc activates BRCA1 gene expression through distal promoter elements in breast cancer cells. Bmc Cancer. 11: 246. PMID 21668996 DOI: 10.1186/1471-2407-11-246 |
0.408 |
|
| 2011 |
Sun C, Huo D, Southard C, Nemesure B, Hennis A, Cristina Leske M, Wu SY, Witonsky DB, Olopade OI, Di Rienzo A. A signature of balancing selection in the region upstream to the human UGT2B4 gene and implications for breast cancer risk. Human Genetics. 130: 767-75. PMID 21660508 DOI: 10.1007/S00439-011-1025-6 |
0.481 |
|
| 2011 |
Im KM, Kirchhoff T, Wang X, Green T, Chow CY, Vijai J, Korn J, Gaudet MM, Fredericksen Z, Shane Pankratz V, Guiducci C, Crenshaw A, McGuffog L, Kartsonaki C, Morrison J, ... ... Olopade OI, et al. Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. Human Genetics. 130: 685-99. PMID 21597964 DOI: 10.1007/S00439-011-1003-Z |
0.422 |
|
| 2011 |
Catenacci DV, Cervantes G, Yala S, Nelson EA, El-Hashani E, Kanteti R, El Dinali M, Hasina R, Brägelmann J, Seiwert T, Sanicola M, Henderson L, Grushko TA, Olopade O, Karrison T, et al. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biology & Therapy. 12: 9-46. PMID 21543897 DOI: 10.4161/Cbt.12.1.15747 |
0.367 |
|
| 2011 |
Sun C, Southard C, Olopade OI, Di Rienzo A. Differential allelic expression of c.1568C > A at UGT2B15 is due to variation in a novel cis-regulatory element in the 3'UTR. Gene. 481: 24-8. PMID 21513781 DOI: 10.1016/J.Gene.2011.04.001 |
0.329 |
|
| 2011 |
Metcalfe K, Gershman S, Lynch HT, Ghadirian P, Tung N, Kim-Sing C, Olopade OI, Domchek S, McLennan J, Eisen A, Foulkes WD, Rosen B, Sun P, Narod SA. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. British Journal of Cancer. 104: 1384-92. PMID 21487411 DOI: 10.1038/Bjc.2011.120 |
0.548 |
|
| 2011 |
Zheng Y, Zhang J, Niu Q, Olopade OI, Huo D. Germline mutational analysis of the C19orf62 gene in African-American women with breast cancer. Breast Cancer Research and Treatment. 127: 871-7. PMID 21431873 DOI: 10.1007/S10549-011-1445-Y |
0.582 |
|
| 2011 |
Souza JAd, Olopade OI. CYP2D6 Genotyping and Tamoxifen: An Unfinished Story in the Quest for Personalized Medicine Seminars in Oncology. 38: 263-273. PMID 21421116 DOI: 10.1053/J.Seminoncol.2011.01.002 |
0.425 |
|
| 2011 |
Spurdle AB, Marquart L, McGuffog L, Healey S, Sinilnikova O, Wan F, Chen X, Beesley J, Singer CF, Dressler AC, Gschwantler-Kaulich D, Blum JL, Tung N, Weitzel J, Lynch H, ... ... Olopade OI, et al. Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 20: 1032-8. PMID 21393566 DOI: 10.1158/1055-9965.Epi-10-0909 |
0.559 |
|
| 2011 |
Metcalfe K, Lynch HT, Ghadirian P, Tung N, Kim-Sing C, Olopade OI, Domchek S, Eisen A, Foulkes WD, Rosen B, Vesprini D, Sun P, Narod SA. Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment. 127: 287-96. PMID 21221768 DOI: 10.1007/S10549-010-1336-7 |
0.568 |
|
| 2011 |
Huo D, Melkonian S, Rathouz PJ, Khramtsov A, Olopade OI. Concordance in histological and biological parameters between first and second primary breast cancers. Cancer. 117: 907-15. PMID 20945326 DOI: 10.1002/Cncr.25587 |
0.546 |
|
| 2011 |
Schrader KA, Masciari S, Boyd N, Salamanca C, Senz J, Saunders DN, Yorida E, Maines-Bandiera S, Kaurah P, Tung N, Robson ME, Ryan PD, Olopade OI, Domchek SM, Ford J, et al. Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers. Journal of Medical Genetics. 48: 64-8. PMID 20921021 DOI: 10.1136/Jmg.2010.079814 |
0.561 |
|
| 2011 |
Campbell MJ, Tonlaar NY, Garwood ER, Huo D, Moore DH, Khramtsov AI, Au A, Baehner F, Chen Y, Malaka DO, Lin A, Adeyanju OO, Li S, Gong C, McGrath M, ... Olopade OI, et al. Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Research and Treatment. 128: 703-11. PMID 20842526 DOI: 10.1007/S10549-010-1154-Y |
0.5 |
|
| 2011 |
Huo D, Liu J, Olopade OI. Discordance in estrogen receptor status between primary, metastatic, and second primary breast cancers: Impact of misclassification. Journal of Clinical Oncology. 29: 578-578. DOI: 10.1200/jco.2011.29.15_suppl.578 |
0.377 |
|
| 2011 |
Gulden C, Moss BT, Olopade OI, Kupfer S. Racial differences in a high-risk colorectal cancer referral population: a single-center experience Hereditary Cancer in Clinical Practice. 9: 15. DOI: 10.1186/1897-4287-9-S1-P15 |
0.382 |
|
| 2011 |
Di L, Wong MM, Wakano CT, Byun J, Varticovski L, Hunter K, Olopade OI, Gardner K. Abstract B33: Transcriptional control of genome surveillance and repair by a metabolic switch Cancer Research. 71. DOI: 10.1158/1538-7445.Fbcr11-B33 |
0.503 |
|
| 2011 |
Huo D, Zheng Y, Ogundiran TO, Adebamowo C, Nathanson KL, Domchek SM, Rebbeck TR, John EM, Hennis A, Nemesure B, Wu S, Ambs S, Niu Q, Zhang J, Cox NJ, ... Olopade OI, et al. Abstract LB-425: Replication of 18 susceptibility loci of breast cancer in women of African ancestry Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-425 |
0.459 |
|
| 2011 |
Zheng Y, Huo D, Zhang J, Yoshimatsu TF, Niu Q, Olopade OI. Abstract 5604: Microsatellites in the estrogen (ESR1, ESR2) and androgen receptor (AR) genes and risk of breast cancer in women of African ancestry Cancer Research. 71: 5604-5604. DOI: 10.1158/1538-7445.Am2011-5604 |
0.542 |
|
| 2011 |
Onel K, Best T, Skol AD, Li D, Kirchhoff T, Yasui Y, Bhatia S, Strong LC, Domchek SM, Nathanson KL, Olopade O, Mack TM, Conti DV, Offit K, Cozen W, et al. Abstract 5092: Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma Cancer Research. 71: 5092-5092. DOI: 10.1158/1538-7445.Am2011-5092 |
0.361 |
|
| 2011 |
Khramtsova GF, Ward J, Khramtsov AI, Hope K, Sveen L, Wu S, Brewster K, Huo D, Nemesure B, Hennis AJM, Olopade OI. Abstract 5066: Molecular profiles of breast cancer in Barbados Cancer Research. 71: 5066-5066. DOI: 10.1158/1538-7445.Am2011-5066 |
0.518 |
|
| 2011 |
Hou N, Ogundiran TO, Adebamowo CA, Olopade OI, Huo D. Abstract 3734: Alcohol consumption and breast cancer risk among Nigerian women Cancer Research. 71: 3734-3734. DOI: 10.1158/1538-7445.Am2011-3734 |
0.47 |
|
| 2011 |
Yoshimatsu TF, Fackenthal JD, Olopade OI. Abstract 2029: Wild type BRCA2 mRNA splice variants in normal and breast tumor cells Cancer Research. 71: 2029-2029. DOI: 10.1158/1538-7445.Am2011-2029 |
0.474 |
|
| 2011 |
Ulasov IV, Kaverina N, Thaci B, Pytel P, Sattar H, Cao D, Hurst DR, Welch DR, Olopade OI, Kadagidze ZG, Lesniak MS. Abstract 1439: Clinical significance of KISS1 protein expression in breast cancer metastasis to brain Cancer Research. 71: 1439-1439. DOI: 10.1158/1538-7445.Am2011-1439 |
0.49 |
|
| 2011 |
Byun JS, Taylor TJ, Wakano C, Di L, Khramtsova G, Olopade OI, Gardner K. Abstract B41: Molecular linkages between metabolic imbalance, genome stability, and triple-negative breast cancer Cancer Epidemiology, Biomarkers & Prevention. 20. DOI: 10.1158/1055-9965.Disp-11-B41 |
0.56 |
|
| 2010 |
Xu J, Chen Y, Olopade OI. MYC and Breast Cancer. Genes & Cancer. 1: 629-40. PMID 21779462 DOI: 10.1177/1947601910378691 |
0.538 |
|
| 2010 |
Antoniou AC, Beesley J, McGuffog L, Sinilnikova OM, Healey S, Neuhausen SL, Ding YC, Rebbeck TR, Weitzel JN, Lynch HT, Isaacs C, Ganz PA, Tomlinson G, Olopade OI, Couch FJ, et al. Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Research. 70: 9742-54. PMID 21118973 DOI: 10.1158/0008-5472.Can-10-1907 |
0.521 |
|
| 2010 |
Domchek SM, Friebel TM, Singer CF, Gareth Evans D, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, Pichert G, Van T'veer L, Tung N, Weitzel JN, Couch FJ, ... ... Olopade OI, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality Jama - Journal of the American Medical Association. 304: 967-975. PMID 20810374 DOI: 10.1001/Jama.2010.1237 |
0.505 |
|
| 2010 |
Ogundiran TO, Huo D, Adenipekun A, Campbell O, Oyesegun R, Akang E, Adebamowo C, Olopade OI. Case-control study of body size and breast cancer risk in Nigerian women American Journal of Epidemiology. 172: 682-690. PMID 20716701 DOI: 10.1093/Aje/Kwq180 |
0.539 |
|
| 2010 |
Zheng Y, Zhang J, Hope K, Niu Q, Huo D, Olopade OI. Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer. Breast Cancer Research and Treatment. 124: 857-61. PMID 20697805 DOI: 10.1007/S10549-010-1095-5 |
0.543 |
|
| 2010 |
Stacey SN, Sulem P, Zanon C, Gudjonsson SA, Thorleifsson G, Helgason A, Jonasdottir A, Besenbacher S, Kostic JP, Fackenthal JD, Huo D, Adebamowo C, Ogundiran T, Olson JE, Fredericksen ZS, ... ... Olopade OI, et al. Ancestry-shift refinement mapping of the C6orf97-ESR1 breast cancer susceptibility locus. Plos Genetics. 6: e1001029. PMID 20661439 DOI: 10.1371/Journal.Pgen.1001029 |
0.436 |
|
| 2010 |
Zhang J, Fackenthal JD, Huo D, Zheng Y, Olopade OI. Searching for large genomic rearrangements of the BRCA1 gene in a Nigerian population. Breast Cancer Research and Treatment. 124: 573-7. PMID 20596889 DOI: 10.1007/S10549-010-1006-9 |
0.523 |
|
| 2010 |
Bradbury AR, Patrick-Miller L, Egleston B, Sands CB, Li T, Schmidheiser H, Feigon M, Ibe CN, Hlubocky FJ, Hope K, Jackson S, Corbman M, Olopade OI, Daly M, Daugherty CK. Parent opinions regarding the genetic testing of minors for BRCA1/2. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 3498-505. PMID 20567018 DOI: 10.1200/Jco.2009.27.2971 |
0.301 |
|
| 2010 |
Medved M, Ivancevic MK, Olopade OI, Newstead GM, Karczmar GS. Echo-planar spectroscopic imaging (EPSI) of the water resonance structure in human breast using sensitivity encoding (SENSE). Magnetic Resonance in Medicine. 63: 1557-63. PMID 20512859 DOI: 10.1002/Mrm.22332 |
0.336 |
|
| 2010 |
Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI, Goss KH. Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. The American Journal of Pathology. 176: 2911-20. PMID 20395444 DOI: 10.2353/Ajpath.2010.091125 |
0.491 |
|
| 2010 |
Sun C, Olopade OI, Di Rienzo A. rs2981582 is associated with FGFR2 expression in normal breast. Cancer Genetics and Cytogenetics. 197: 193-4. PMID 20193855 DOI: 10.1016/J.Cancergencyto.2009.11.006 |
0.454 |
|
| 2010 |
Domchek SM, Friebel TM, Garber JE, Isaacs C, Matloff E, Eeles R, Evans DG, Rubinstein W, Singer CF, Rubin S, Lynch HT, Daly MB, Weitzel J, Ganz PA, Pichert G, ... Olopade OI, et al. Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers Breast Cancer Research and Treatment. 124: 195-203. PMID 20180014 DOI: 10.1007/S10549-010-0799-X |
0.486 |
|
| 2010 |
Burness ML, Grushko TA, Olopade OI. Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker? Cancer Journal. 16: 23-32. PMID 20164687 DOI: 10.1097/Ppo.0B013E3181D24Fc1 |
0.5 |
|
| 2010 |
Gulden C, Olopade OI. Risk assessment and genetic testing for ovarian cancer. American Journal of Roentgenology. 194: 309-310. PMID 20093589 DOI: 10.2214/Ajr.09.3999 |
0.459 |
|
| 2010 |
Malaka DO, Olopade OI. Estrogen deprivation therapy and colon cancer risk in breast cancer patients. Breast Journal. 16: 110-112. PMID 19929891 DOI: 10.1111/J.1524-4741.2009.00862.X |
0.528 |
|
| 2010 |
Medved M, Newstead GM, Abe H, Olopade OI, Shimauchi A, Zamora MA, Karczmar GS. Clinical implementation of a multislice high spectral and spatial resolution-based MRI sequence to achieve unilateral full-breast coverage. Magnetic Resonance Imaging. 28: 16-21. PMID 19628350 DOI: 10.1016/J.Mri.2009.05.022 |
0.316 |
|
| 2010 |
Xu J, Huo D, Chen Y, Nwachukwu C, Collins C, Rowell J, Slamon DJ, Olopade OI. CpG island methylation affects accessibility of the proximal BRCA1 promoter to transcription factors Breast Cancer Research and Treatment. 120: 593-601. PMID 19466541 DOI: 10.1007/S10549-009-0422-1 |
0.326 |
|
| 2010 |
Lee RT, Cohen L, Olopade OI, Curlin FC. National survey of U.S. oncologists' knowledge, attitudes, and practice patterns regarding herb and supplement use by cancer patients. Journal of Clinical Oncology. 28: 9109-9109. DOI: 10.1200/Jco.2010.28.15_Suppl.9109 |
0.35 |
|
| 2010 |
Polite BN, Smith DM, Ray M, Hlubocky FJ, Olopade OI, Daugherty C, Gehlert SJ. Evaluating psychosocial and belief differences in a diverse racial and socioeconomic cancer population. Journal of Clinical Oncology. 28: 6036-6036. DOI: 10.1200/Jco.2010.28.15_Suppl.6036 |
0.387 |
|
| 2010 |
Adeniji KA, Huo D, Khramtsov A, Zhang C, Olopade OI. Molecular profiles of breast cancer in Ilorin, Nigeria. Journal of Clinical Oncology. 28: 1602-1602. DOI: 10.1200/Jco.2010.28.15_Suppl.1602 |
0.403 |
|
| 2010 |
Grushko TA, Nwachukwu C, Charoenthammaraksa S, Huo D, Khramtsov A, Mashek H, Zhang C, Xu J, Perou CM, Olopade OI. Evaluation of BRCA1 inactivation by promoter methylation as a marker of triple-negative and basal-like breast cancers. Journal of Clinical Oncology. 28: 10510-10510. DOI: 10.1200/Jco.2010.28.15_Suppl.10510 |
0.393 |
|
| 2010 |
Nwachukwu C, Zhang C, Duan S, Huo D, Minn A, Perou C, Olopade O. Abstract 3004: Specific microRNAs associate with aggressive breast tumor phenotypes in an ethnically diverse patient cohort Cancer Research. 70: 3004-3004. DOI: 10.1158/1538-7445.Am10-3004 |
0.396 |
|
| 2010 |
Sylvester BE, Huo D, Khramtsov A, Zhang J, Smalling R, Polite B, Olopade OI. Abstract 28: Molecular analysis of colorectal cancer progression in an ethnically diverse cohort reveals a higher prevalence of KRAS mutations in African Americans Cancer Research. 70: 28-28. DOI: 10.1158/1538-7445.Am10-28 |
0.777 |
|
| 2010 |
Kasvosve NN, Fackenthal J, Zhang J, Olopade O. Abstract 1859: Breast cancer risk:tp53 genotyping in a Nigerian population Cancer Research. 70: 1859-1859. DOI: 10.1158/1538-7445.Am10-1859 |
0.535 |
|
| 2010 |
Lubin GP, Khramtsov A, Khramtsova G, Sveen WE, Perou CM, Huo D, Olopade OI. Abstract 1176: αB-Crystallin expression across different stages and subtypes of breast cancer analyzed using tissue microarrays Cancer Research. 70: 1176-1176. DOI: 10.1158/1538-7445.Am10-1176 |
0.53 |
|
| 2010 |
Yoshimatsu TF, Fackenthal J, Burrill D, Fleming G, Olopade O. Abstract 1112: Splicing regulation and BRCA1/2-associated breast cancer risk Cancer Research. 70: 1112-1112. DOI: 10.1158/1538-7445.Am10-1112 |
0.511 |
|
| 2010 |
Adeyanju O, Khramtsov A, Verma A, Liu L, Wang X, Sattar H, Olopade O, Huo D. Abstract P6-01-06: Identification of Molecular Subtypes of DCIS and Invasive Breast Cancer Using Computerized Image Analysis for Data Integration Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P6-01-06 |
0.362 |
|
| 2010 |
Li H, Giger ML, Lan L, Yuan Y, Bhooshan N, Olopade OI. Effect of variable gain on computerized texture analysis on digitalized mammograms Proceedings of Spie. 7624. DOI: 10.1117/12.845321 |
0.478 |
|
| 2009 |
Malaka DO, Lee R, Lewin R, Cummings S, Curlin F, Bradbury A, Olopade O. Lifestyle modifications including complementary and alternative medicine and quality of life among women at high risk for breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e20583. PMID 27961203 DOI: 10.1200/Jco.2009.27.15_Suppl.E20583 |
0.348 |
|
| 2009 |
Neuhausen SL, Brummel S, Ding YC, Singer CF, Pfeiler G, Lynch HT, Nathanson KL, Rebbeck TR, Garber JE, Couch F, Weitzel J, Narod SA, Ganz PA, Daly MB, Godwin AK, ... ... Olopade OI, et al. Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers. Breast Cancer Research : Bcr. 11: R76. PMID 19843326 DOI: 10.1186/Bcr2414 |
0.524 |
|
| 2009 |
Hong S, Nekhlyudov L, Didwania A, Olopade O, Ganschow P. Cancer Survivorship Care: Exploring the Role of the General Internist Journal of General Internal Medicine. 24: 495-500. PMID 19838857 DOI: 10.1007/S11606-009-1019-4 |
0.427 |
|
| 2009 |
Hong S, Didwania A, Olopade O, Ganschow P. The expanding use of third-generation aromatase inhibitors: what the general internist needs to know. Journal of General Internal Medicine. 24: 383-388. PMID 19838836 DOI: 10.1007/S11606-009-1037-2 |
0.527 |
|
| 2009 |
Medved M, Newstead GM, Fan X, Du YP, Olopade OI, Shimauchi A, Zamora MA, Karczmar GS. Fourier component imaging of water resonance in the human breast provides markers for malignancy. Physics in Medicine and Biology. 54: 5767-79. PMID 19741276 DOI: 10.1088/0031-9155/54/19/007 |
0.315 |
|
| 2009 |
Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, Zhang B, Grushko T, Zhang C, Oluwasola O, Malaka D, Malami S, Odetunde A, Adeoye AO, Iyare F, ... ... Olopade OI, et al. Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4515-21. PMID 19704069 DOI: 10.1200/Jco.2008.19.6873 |
0.506 |
|
| 2009 |
Rebbeck TR, Mitra N, Domchek SM, Wan F, Chuai S, Friebel TM, Panossian S, Spurdle A, Chenevix-Trench G, Singer CF, Pfeiler G, Neuhausen SL, Lynch HT, Garber JE, ... ... Olopade OI, et al. Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers. Cancer Research. 69: 5801-10. PMID 19584272 DOI: 10.1158/0008-5472.Can-09-0625 |
0.491 |
|
| 2009 |
Hu Z, Fan C, Livasy C, He X, Oh DS, Ewend MG, Carey LA, Subramanian S, West R, Ikpatt F, Olopade OI, van de Rijn M, Perou CM. A compact VEGF signature associated with distant metastases and poor outcomes. Bmc Medicine. 7: 9. PMID 19291283 DOI: 10.1186/1741-7015-7-9 |
0.408 |
|
| 2009 |
Huo D, Senie RT, Daly M, Buys SS, Cummings S, Ogutha J, Hope K, Olopade OI. Prediction of BRCA Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United States. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1184-90. PMID 19188678 DOI: 10.1200/Jco.2008.17.5869 |
0.375 |
|
| 2009 |
Bradbury AR, Patrick-Miller L, Pawlowski K, Ibe CN, Cummings SA, Hlubocky F, Olopade OI, Daugherty CK. Learning of your parent's BRCA mutation during adolescence or early adulthood: a study of offspring experiences. Psycho-Oncology. 18: 200-8. PMID 18702049 DOI: 10.1002/Pon.1384 |
0.348 |
|
| 2009 |
Zhang B, Fackenthal JD, Niu Q, Huo D, Sveen WE, DeMarco T, Adebamowo CA, Ogundiran T, Olopade OI. Evidence for an ancient BRCA1 mutation in breast cancer patients of Yoruban ancestry. Familial Cancer. 8: 15-22. PMID 18679828 DOI: 10.1007/S10689-008-9205-9 |
0.506 |
|
| 2009 |
Belova L, Delgado B, Kocherginsky M, Melhem A, Olopade OI, Conzen SD. Glucocorticoid receptor expression in breast cancer associates with older patient age. Breast Cancer Research and Treatment. 116: 441-7. PMID 18668364 DOI: 10.1007/S10549-008-0136-9 |
0.453 |
|
| 2009 |
Olopade O. A family-based approach to primary prevention of breast cancer Journal of Clinical Oncology. 27. DOI: 10.1200/Jco.2009.27.15_Suppl.S2 |
0.562 |
|
| 2009 |
Cerri E, Spyrka S, Huo D, Khramtsov A, Khramtsova G, Olopade O, Innocenti F, Nanda R. The role of VEGFR-2 genetic variation in breast cancer progression. Cancer Research. 69: 904. DOI: 10.1158/0008-5472.Sabcs-904 |
0.305 |
|
| 2009 |
Garwood E, Kumar A, Baehner F, Garber J, Troyan S, Olopade O, Moore D, Au A, Flowers C, Campbell M, Hylton N, Esserman L, Rush-Port E. Fluvastatin has biologic effects on stage 0 and 1 breast cancer. Cancer Research. 69: 4122. DOI: 10.1158/0008-5472.Sabcs-4122 |
0.344 |
|
| 2009 |
Nwachukwu C, Grushko T, Xu J, Khramtsov A, Olopade O. BRCA1 methylation contributes to the triple-negative breast cancer phenotype. Cancer Research. 69: 4050. DOI: 10.1158/0008-5472.Sabcs-4050 |
0.408 |
|
| 2009 |
Malaka D, Khramtsov A, Oluwasola O, Odetunde A, Falusi A, Grushko T, Huo D, Olopade O. Validation of breast cancer biomarkers between a field immunohistochemistry laboratory in Nigeria and its US-based counterpart. Cancer Research. 69: 4039. DOI: 10.1158/0008-5472.Sabcs-4039 |
0.407 |
|
| 2009 |
Huo D, Melkonian S, Rathouz P, Khramtsov A, Olopade O. Concordance in Hormone Receptor Status between First and Second Breast Cancers. Cancer Research. 69: 4144-4144. DOI: 10.1158/0008-5472.Sabcs-09-4144 |
0.469 |
|
| 2009 |
Cobain E, Hong S, Abe H, Jansen S, Jaskowiak N, Newstead G, Olopade O. The Effect of Preoperative MRI on Mastectomy Rates in Breast Cancer Patients. Cancer Research. 69: 4019-4019. DOI: 10.1158/0008-5472.Sabcs-09-4019 |
0.411 |
|
| 2009 |
Rajagopal P, Fackenthal J, Huo D, Niu Q, Zhang J, Kirchhoff T, Offit K, Olopade O. Genetic Risks for Breast Cancer in African American Women: Analysis of Candidate Single Nucleotide Polymorphisms from Association Studies. Cancer Research. 69: 3068-3068. DOI: 10.1158/0008-5472.Sabcs-09-3068 |
0.443 |
|
| 2009 |
Tonlaar N, Campbell M, Garwood E, Khramtsov A, Moore D, Au A, Baehner F, Huo D, David M, Oluwasola O, Odetunde A, Tretiakova M, Li S, Gong C, Tonner E, ... ... Olopade O, et al. Association of Proliferating Macrophages with High Grade, Hormone Receptor Negative Breast Cancer. Cancer Research. 69: 3042-3042. DOI: 10.1158/0008-5472.Sabcs-09-3042 |
0.365 |
|
| 2008 |
Olopade OI, Grushko TA, Nanda R, Huo D. Advances in breast cancer: pathways to personalized medicine. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 7988-99. PMID 19088015 DOI: 10.1158/1078-0432.Ccr-08-1211 |
0.581 |
|
| 2008 |
Chen Y, Olopade OI. MYC in breast tumor progression. Expert Review of Anticancer Therapy. 8: 1689-98. PMID 18925859 DOI: 10.1586/14737140.8.10.1689 |
0.526 |
|
| 2008 |
Hall MJ, Dignam JJ, Olopade OI. Family history of pancreatic cancer in a high-risk cancer clinic: implications for risk assessment. Journal of Genetic Counseling. 17: 365-72. PMID 18581219 DOI: 10.1007/S10897-008-9154-3 |
0.392 |
|
| 2008 |
Narod SA, Neuhausen S, Vichodez G, Armel S, Lynch HT, Ghadirian P, Cummings S, Olopade O, Stoppa-Lyonnet D, Couch F, Wagner T, Warner E, Foulkes WD, Saal H, Weitzel J, et al. Rapid progression of prostate cancer in men with a BRCA2 mutation. British Journal of Cancer. 99: 371-4. PMID 18577985 DOI: 10.1038/Sj.Bjc.6604453 |
0.378 |
|
| 2008 |
Stacey SN, Manolescu A, Sulem P, Thorlacius S, Gudjonsson SA, Jonsson GF, Jakobsdottir M, Bergthorsson JT, Gudmundsson J, Aben KK, Strobbe LJ, Swinkels DW, van Engelenburg KC, Henderson BE, Kolonel LN, ... ... Olopade OI, et al. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nature Genetics. 40: 703-6. PMID 18438407 DOI: 10.1038/Ng.131 |
0.481 |
|
| 2008 |
Hua S, Kallen CB, Dhar R, Baquero MT, Mason CE, Russell BA, Shah PK, Liu J, Khramtsov A, Tretiakova MS, Krausz TN, Olopade OI, Rimm DL, White KP. Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression. Molecular Systems Biology. 4: 188. PMID 18414489 DOI: 10.1038/Msb.2008.25 |
0.477 |
|
| 2008 |
Argos M, Kibriya MG, Jasmine F, Olopade OI, Su T, Hibshoosh H, Ahsan H. Genomewide scan for loss of heterozygosity and chromosomal amplification in breast carcinoma using single-nucleotide polymorphism arrays. Cancer Genetics and Cytogenetics. 182: 69-74. PMID 18406867 DOI: 10.1016/J.Cancergencyto.2008.01.001 |
0.385 |
|
| 2008 |
Antoniou AC, Spurdle AB, Sinilnikova OM, Healey S, Pooley KA, Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, Hofmann W, Sutter C, Niederacher D, Deissler H, Caldes T, ... ... Olopade OI, et al. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. American Journal of Human Genetics. 82: 937-48. PMID 18355772 DOI: 10.1016/J.Ajhg.2008.02.008 |
0.544 |
|
| 2008 |
Bradbury AR, Ibe CN, Dignam JJ, Cummings SA, Verp M, White MA, Artioli G, Dudlicek L, Olopade OI. Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 10: 161-6. PMID 18344704 DOI: 10.1097/Gim.0B013E318163487D |
0.424 |
|
| 2008 |
Gehlert S, Sohmer D, Sacks T, Mininger C, McClintock M, Olopade O. Targeting health disparities: a model linking upstream determinants to downstream interventions. Health Affairs (Project Hope). 27: 339-49. PMID 18332488 DOI: 10.1377/Hlthaff.27.2.339 |
0.336 |
|
| 2008 |
Huo D, Adebamowo CA, Ogundiran TO, Akang EE, Campbell O, Adenipekun A, Cummings S, Fackenthal J, Ademuyiwa F, Ahsan H, Olopade OI. Parity and breastfeeding are protective against breast cancer in Nigerian women. British Journal of Cancer. 98: 992-6. PMID 18301401 DOI: 10.1038/Sj.Bjc.6604275 |
0.536 |
|
| 2008 |
Garner CP, Ding YC, John EM, Ingles SA, Olopade OI, Huo D, Adebamowo C, Ogundiran T, Neuhausen SL. Genetic variation in IGFBP2 and IGFBP5 is associated with breast cancer in populations of African descent. Human Genetics. 123: 247-55. PMID 18210156 DOI: 10.1007/S00439-008-0468-X |
0.549 |
|
| 2008 |
Bradbury AR, Patrick-Miller L, Pawlowski K, Ibe CN, Cummings SA, Olopade OI, Daugherty CK. Should genetic testing for BRCA1/2 be permitted for minors? Opinions of BRCA mutation carriers and their adult offspring. American Journal of Medical Genetics. Part C, Seminars in Medical Genetics. 148: 70-7. PMID 18200524 DOI: 10.1002/Ajmg.C.30163 |
0.344 |
|
| 2008 |
Li H, Giger ML, Olopade OI, Chinander MR. Power spectral analysis of mammographic parenchymal patterns for breast cancer risk assessment. Journal of Digital Imaging. 21: 145-52. PMID 18175183 DOI: 10.1007/S10278-007-9093-9 |
0.478 |
|
| 2008 |
Gao B, Xie XJ, Huang C, Shames DS, Chen TT, Lewis CM, Bian A, Zhang B, Olopade OI, Garber JE, Euhus DM, Tomlinson GE, Minna JD. RASSF1A polymorphism A133S is associated with early onset breast cancer in BRCA1/2 mutation carriers. Cancer Research. 68: 22-5. PMID 18172292 DOI: 10.1158/0008-5472.Can-07-5183 |
0.54 |
|
| 2008 |
Grushko TA, Filiaci VL, Mundt AJ, Ridderstråle K, Olopade OI, Fleming GF. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: A gynecologic oncology group study Gynecologic Oncology. 108: 3-9. PMID 17945336 DOI: 10.1016/J.Ygyno.2007.09.007 |
0.362 |
|
| 2008 |
Wei M, Xu J, Dignam J, Nanda R, Sveen L, Fackenthal J, Grushko TA, Olopade OI. Estrogen receptor α, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers Breast Cancer Research and Treatment. 111: 113-120. PMID 17932744 DOI: 10.1007/S10549-007-9766-6 |
0.443 |
|
| 2008 |
Huo D, Kim HJ, Adebamowo CA, Ogundiran TO, Akang EE, Campbell O, Adenipekun A, Niu Q, Sveen L, Fackenthal JD, Fackenthal DL, Das S, Cox N, Di Rienzo A, Olopade OI. Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and breast cancer risk in Africans. Breast Cancer Research and Treatment. 110: 367-76. PMID 17909964 DOI: 10.1007/S10549-007-9720-7 |
0.504 |
|
| 2008 |
Bradbury AR, Patrick-Miller L, Feigon M, Pawlowski K, Egleston B, Ibe C, Sands CB, Cummings S, Olopade OI, Daugherty CK. Should genetic testing for BRCA1/2 be permitted for minors? Opinions of parents who completed BRCA1/2 testing Journal of Clinical Oncology. 26: 1511-1511. DOI: 10.1200/Jco.2008.26.15_Suppl.1511 |
0.33 |
|
| 2008 |
Ogundiran TO, Huo D, Adebamowo CA, Adenipekun AA, Campbell OB, Olopade OI. Case-control study of height, weight and BMI and breast cancer risk in Nigerian women Journal of Clinical Oncology. 26: 1506-1506. DOI: 10.1200/Jco.2008.26.15_Suppl.1506 |
0.472 |
|
| 2008 |
Huo D, Olopade OI. Abstract 3839: Is recent decline in breast cancer incidence equal across different US racial groups? Epidemiology. DOI: 10.1158/1538-7445.Am2008-3839 |
0.505 |
|
| 2008 |
Harms S, Early A, Bevers TB, Giuliano A, Golshan M, Hertz IH, Kiel KD, Kivitz PB, Leitch AM, Overmoyer BA, Vargas HI, Silva E, Siziopikou KP, Shriver CD, Olopade O. American Society of Breast Disease Policy Statement on The Use of Breast Magnetic Resonance Imaging Seminars in Breast Disease. 11: 111-112. DOI: 10.1053/J.Sembd.2008.06.001 |
0.391 |
|
| 2007 |
Huo D, Olopade OI. Genetic testing in diverse populations: are researchers doing enough to get out the correct message? Jama. 298: 2910-1. PMID 18159061 DOI: 10.1001/Jama.298.24.2910 |
0.54 |
|
| 2007 |
Fackenthal JD, Olopade OI. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations Nature Reviews Cancer. 7: 937-948. PMID 18034184 DOI: 10.1038/Nrc2054 |
0.501 |
|
| 2007 |
Antoniou AC, Sinilnikova OM, Simard J, Léoné M, Dumont M, Neuhausen SL, Struewing JP, Stoppa-Lyonnet D, Barjhoux L, Hughes DJ, Coupier I, Belotti M, Lasset C, Bonadona V, Bignon YJ, ... ... Olopade OI, et al. RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. American Journal of Human Genetics. 81: 1186-200. PMID 17999359 DOI: 10.1086/522611 |
0.489 |
|
| 2007 |
Bell DW, Kim SH, Godwin AK, Schiripo TA, Harris PL, Haserlat SM, Wahrer DC, Haiman CA, Daly MB, Niendorf KB, Smith MR, Sgroi DC, Garber JE, Olopade OI, Le Marchand L, et al. Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. International Journal of Cancer. Journal International Du Cancer. 121: 2661-7. PMID 17721994 DOI: 10.1002/Ijc.23026 |
0.565 |
|
| 2007 |
Bradbury AR, Dignam JJ, Ibe CN, Auh SL, Hlubocky FJ, Cummings SA, White M, Olopade OI, Daugherty CK. How often do BRCA mutation carriers tell their young children of the family's risk for cancer? A study of parental disclosure of BRCA mutations to minors and young adults. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 3705-11. PMID 17704419 DOI: 10.1200/Jco.2006.09.1900 |
0.347 |
|
| 2007 |
Couch FJ, Sinilnikova O, Vierkant RA, Pankratz VS, Fredericksen ZS, Stoppa-Lyonnet D, Coupier I, Hughes D, Hardouin A, Berthet P, Peock S, Cook M, Baynes C, Hodgson S, Morrison PJ, ... ... Olopade OI, et al. AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 16: 1416-21. PMID 17627006 DOI: 10.1158/1055-9965.EPI-07-0129 |
0.467 |
|
| 2007 |
Bradbury AR, Olopade OI. Genetic susceptibility to breast cancer. Reviews in Endocrine & Metabolic Disorders. 8: 255-67. PMID 17508290 DOI: 10.1007/S11154-007-9038-0 |
0.568 |
|
| 2007 |
Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S, Backlund MG, Yin Y, Khramtsov AI, Bastein R, Quackenbush J, ... ... Olopade OI, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biology. 8: R76. PMID 17493263 DOI: 10.1186/Gb-2007-8-5-R76 |
0.365 |
|
| 2007 |
Hong AL, Huo D, Kim HJ, Niu Q, Fackenthal DL, Cummings SA, John EM, West DW, Whittemore AS, Das S, Olopade OI. UDP-Glucuronosyltransferase 1A1 gene polymorphisms and total bilirubin levels in an ethnically diverse cohort of women. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 35: 1254-61. PMID 17478602 DOI: 10.1124/Dmd.106.014183 |
0.308 |
|
| 2007 |
Li H, Giger ML, Olopade OI, Lan L. Fractal analysis of mammographic parenchymal patterns in breast cancer risk assessment. Academic Radiology. 14: 513-21. PMID 17434064 DOI: 10.1016/J.Acra.2007.02.003 |
0.487 |
|
| 2007 |
Nanda R, Huo D, Cook M, Chen L, Hope K, Cummings S, Olopade OI. Outcomes after breast cancer in an ethnically diverse cohort of high-risk patients: Differences in survival based on BRCA1/BRCA2 mutation status Journal of Clinical Oncology. 25: 21116-21116. DOI: 10.1200/Jco.2007.25.18_Suppl.21116 |
0.564 |
|
| 2007 |
Collins C, Huo D, Xu J, Bleibel WK, Dolan ME, Olopade OI, Nanda R. Relationship between BRCA1 promoter methylation and sensitivity of breast cancer cell lines to cisplatin and paclitaxel Journal of Clinical Oncology. 25: 21083-21083. DOI: 10.1200/Jco.2007.25.18_Suppl.21083 |
0.474 |
|
| 2007 |
Bradbury AR, Cummings SA, Dignam JJ, Patrick-Miller L, Verp M, White MA, Dudlicek L, Newstead G, Abe H, Schmidt R, Olopade OI. Health-related quality of life among high-risk women in an MRI surveillance study Journal of Clinical Oncology. 25: 1522-1522. DOI: 10.1200/Jco.2007.25.18_Suppl.1522 |
0.361 |
|
| 2007 |
Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, Ghadirian P, Friedman E, Foulkes WD, Kim-Sing C, Wagner T, Tung N, Couch F, Stoppa-Lyonnet D, ... ... Olopade OI, et al. Salpingo-oophorectomy and the Risk of Ovarian, Fallopian Tube, and Peritoneal Cancers in Women with a BRCA1 or BRCA2 Mutation Obstetrical & Gynecological Survey. 62: 29-31. DOI: 10.1097/01.Ogx.0000251480.69322.50 |
0.487 |
|
| 2006 |
Shames DS, Girard L, Gao B, Sato M, Lewis CM, Shivapurkar N, Jiang A, Perou CM, Kim YH, Pollack JR, Fong KM, Lam CL, Wong M, Shyr Y, Nanda R, ... Olopade OI, et al. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. Plos Medicine. 3: e486. PMID 17194187 DOI: 10.1371/Journal.Pmed.0030486 |
0.41 |
|
| 2006 |
Fan X, Abe H, Medved M, Foxley S, Arkani S, Zamora MA, Olopade OI, Newstead GM, Karczmar GS. Fat suppression with spectrally selective inversion vs. high spectral and spatial resolution MRI of breast lesions: qualitative and quantitative comparisons. Journal of Magnetic Resonance Imaging : Jmri. 24: 1311-5. PMID 17096393 DOI: 10.1002/Jmri.20732 |
0.313 |
|
| 2006 |
Kodl MM, Lee JW, Matthews AK, Cummings SA, Olopade OI. Correlates of depressive symptoms among women seeking cancer genetic counseling and risk assessment at a high-risk cancer clinic. Journal of Genetic Counseling. 15: 267-76. PMID 16897360 DOI: 10.1007/S10897-006-9025-8 |
0.356 |
|
| 2006 |
Locker GY, Kaul K, Weinberg DS, Gatalica Z, Gong G, Peterman A, Lynch J, Klatzco L, Olopade OI, Bomzer CA, Newlin A, Keenan E, Tajuddin M, Knezetic J, Coronel S, et al. The I1307K APC polymorphism in Ashkenazi Jews with colorectal cancer: clinical and pathologic features. Cancer Genetics and Cytogenetics. 169: 33-8. PMID 16875934 DOI: 10.1016/J.Cancergencyto.2006.03.007 |
0.45 |
|
| 2006 |
Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, Ghadirian P, Friedman E, Foulkes WD, Kim-Sing C, Wagner T, Tung N, Couch F, Stoppa-Lyonnet D, ... ... Olopade OI, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. Jama. 296: 185-92. PMID 16835424 DOI: 10.1001/Jama.296.2.185 |
0.425 |
|
| 2006 |
Salant T, Ganschow PS, Olopade OI, Lauderdale DS. "Why take it if you don't have anything?" breast cancer risk perceptions and prevention choices at a public hospital. Journal of General Internal Medicine. 21: 779-85. PMID 16808782 DOI: 10.1111/J.1525-1497.2006.00461.X |
0.441 |
|
| 2006 |
Hall MJ, Olopade OI. Disparities in genetic testing: thinking outside the BRCA box. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 2197-203. PMID 16682739 DOI: 10.1200/Jco.2006.05.5889 |
0.386 |
|
| 2006 |
Polite BN, Dignam JJ, Olopade OI. Colorectal cancer model of health disparities: understanding mortality differences in minority populations. Journal of Clinical Oncology. 24: 2179-2187. PMID 16682737 DOI: 10.1200/Jco.2005.05.4775 |
0.428 |
|
| 2006 |
Olopade OI, Schwartsmann G, Saijo N, Thomas CR. Disparities in cancer care: A worldwide perspective and roadmap for change Journal of Clinical Oncology. 24: 2135-2136. PMID 16682731 DOI: 10.1200/Jco.2006.06.7918 |
0.361 |
|
| 2006 |
Chen Y, Borowicz S, Fackenthal J, Collart FR, Myatt E, Moy S, Babnigg G, Wilton R, Boernke WE, Schiffer M, Stevens FJ, Olopade OI. Primary structure-based function characterization of BRCT domain replicates in BRCA1. Biochemical and Biophysical Research Communications. 345: 188-96. PMID 16677609 DOI: 10.1016/J.Bbrc.2006.03.239 |
0.339 |
|
| 2006 |
Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, Nobel A, Parker J, Ewend MG, Sawyer LR, Wu J, ... ... Olopade OI, et al. The molecular portraits of breast tumors are conserved across microarray platforms. Bmc Genomics. 7: 96. PMID 16643655 DOI: 10.1186/1471-2164-7-96 |
0.421 |
|
| 2006 |
Pierce LJ, Levin AM, Rebbeck TR, Ben-David MA, Friedman E, Solin LJ, Harris EE, Gaffney DK, Haffty BG, Dawson LA, Narod SA, Olivotto IA, Eisen A, Whelan TJ, Olopade OI, et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 2437-43. PMID 16636335 DOI: 10.1200/Jco.2005.02.7888 |
0.506 |
|
| 2006 |
Perreard L, Fan C, Quackenbush JF, Mullins M, Gauthier NP, Nelson E, Mone M, Hansen H, Buys SS, Rasmussen K, Orrico AR, Dreher D, Walters R, Parker J, Hu Z, ... ... Olopade OI, et al. Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Research : Bcr. 8: R23. PMID 16626501 DOI: 10.1186/Bcr1399 |
0.521 |
|
| 2006 |
Olopade OI. Using genetic analysis to individualize preventive measures for breast and ovarian cancers Nature Reviews Clinical Oncology. 3: 182-183. PMID 16596140 DOI: 10.1038/Ncponc0456 |
0.51 |
|
| 2006 |
Friedman E, Kotsopoulos J, Lubinski J, Lynch HT, Ghadirian P, Neuhausen SL, Isaacs C, Weber B, Foulkes WD, Moller P, Rosen B, Kim-Sing C, Gershoni-Baruch R, Ainsworth P, Daly M, ... ... Olopade OI, et al. Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. Breast Cancer Research : Bcr. 8: R15. PMID 16563180 DOI: 10.1186/Bcr1387 |
0.533 |
|
| 2006 |
Domchek SM, Friebel TM, Neuhausen SL, Wagner T, Evans G, Isaacs C, Garber JE, Daly MB, Eeles R, Matloff E, Tomlinson GE, Van't Veer L, Lynch HT, Olopade OI, Weber BL, et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. The Lancet. Oncology. 7: 223-9. PMID 16510331 DOI: 10.1016/S1470-2045(06)70585-X |
0.462 |
|
| Show low-probability matches. |